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Chapter 1 
Introduction 
1.1 Thiosemicarbazones 
Thiosemicarbazones form an important class of organic compounds thanks to their 
structural, chemical and biological activities. Thiosemicarbazone derivatives are 
formally obtained by condensation of the terminal N of the hydrazine group of a 
thiosemicarbazide with a carbonyl group of a ketone or an aldehyde of aliphatic or 
aromatic nature (Fig. 1.1). 
 
 
 
 
Figure 1.1 - Synthesis of a generic thiosemicarbazone 
 
The starting thiosemicarbazides can be prepared by a series of synthetic procedures 
(Fig. 1.2) such as, for instance, the reaction of amines with carbon disulphide or 
thiophosgene followed of the addition of hydrazine or the reaction of hydrazine with 
isothiocyanates
1
. 
6 
 
 
 
Figure 1.2 – Thiosemicarbazide synthesis 
 
Thiosemicarbazones chemical interest dates back to the beginning of the 20th century 
but the first reports on their medical applications began to appear in the Fifties as drugs 
against tuberculosis and leprosy. 
In 1946 Domagk reported the antitubercular activity in vitro of some 
thiosemicarbazones derived from cyclic ketones and aldehydes
2
. Subsequently other 
tests against tuberculosis were done by Hoggart et al.
3
 using different kind of 
thiosemicarbazones (aliphatic and aromatic) variously substituted at N2 and N4. Tests 
on acute Mycrobacterium tubercolosis in mice revealed that thiosemicarbazones 
obtained from aromatic aldehydes possessed marked activity. In this screening the 
highest activity was associated to a para substituent in the aromatic ring. The 
antileukemic effect of 2-formylpyridine thiosemicarbazone was first reported Brockman 
et al. during the Fifties
3
 while during the Sixties a new thiosemicarbazone was 
developed and commercialized, Marboran
®
 (Methisazone, N-methilisatin-8-
thiosemicarbazone) (Fig. 1.3). Marboran
®
 was therefore used to treat smallpox thanks to 
its ability to inhibit the mRNA and protein synthesis especially in pox viruses
2
 and 
herpes simplex virus (HSV)
4
. 
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Figure 1.3 – Marboran® (Methisazone) 
 
More recently its N4-diethyl and N4-allyl derivatives were discovered to have a 
significant and selective inhibition activity on structural protein synthesis in human 
immunodeficiency virus (HIV) infected cells
5
. 
After the discovery of antitumor properties of pyridine-2-carboxyhaldehyde 
thiosemicarbazone a large number of different ring systems (benzene, thiophene, furan, 
etc) have been synthesized and evaluated for antineoplastic activity. Interestingly the 
most active compounds revealed to be six membered heterocyclic rings carrying the 
thiosemicarbazone side-chain in α position to the heterocyclic nitrogen while 
compounds bearing the side chain in β or γ position to the ring nitrogen resulted to be 
inactive
1,6
. Despite the activity of these compounds their poor solubility played a central 
role in the discovery of one of the most promising drugs in cancer therapy, Triapine
® 
(Fig.1.4).  
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Figure 1.4 - 3-aminopyridine-2-carboxaldehyde thiosemicarbazone  
(Triapine
®
, Vion Pharmaceuticals) 
 
Triapine
®
 or 3-AP has been developed by Alan Sartorelli (Yale University School of 
Medicine) during attempts to study and to optimize isoquinoline and pyridine 
thiosemicarbazones solubility using as functional groups hydrophilic groups
7
. An amino 
group resulted to be the best option for both the heterocyclic systems. The best positions 
to be substituted were 5 for isoquinoline and 3 and 5 for pyridine. In particular the 3-
aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine
®
) derivative appeared to 
be the most promising. This compound is currently used in Phase II clinical trials (Vion 
Pharmaceuticals)
8,9
. 
 
1.1.2 Thiosemicarbazones as metal chelators 
Focusing on the structural characteristics, thiosemicarbazones are characterized by a 
N,S set of donor atoms (Fig. 1.5) which render them good metal chelating agents. 
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Figure 1.5 – Donor atoms of thiosemicarbazones 
 
The coordination chemistry of thiosemicarbazones appears to be very interesting 
because of their versatility in coordinating metal ions and their ability to stabilize 
various oxidation states of metals thanks to their donor atoms
1,10
. Also the biological 
activity of the organic molecules has often been ascribed to their ability to chelate 
endogenous metals to form metal complexes which are the active species. 
In solution thiosemicarbazones exist in two tautomeric forms thione and thiol (Fig.1.6) 
and this has a remarkable effect on their chemical properties
1
. 
 
 
 
Figure 1.6 – Thione-thiol equilibrium 
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In the solid state, most of the thiosemicarbazones adopt a trans configuration in which 
the sulphur atom is in trans position to the azomethine nitrogen atom, this conformation 
could be adopted to favor the formation of intramolecular hydrogen bonding between 
N4 and N1
1
. 
However in most of the thiosemicarbazonic complexes the ligand binds the metal 
adopting a cis configuration. Denticity of thiosemicarbazone can also be increased if the 
starting aldehyde or ketone possesses a functional group in a position suitable for 
chelation (Fig.1.7). When the thiosemicarbazone side chain is attached in α position to a 
α-N-heterocyclic ring, thiosemicarbazones have shown substantial in vitro activity 
against various human tumour lines
6
. 
 
 
Figure 1.7 – Tridentatate heterocyclic ligand 
   
The presence of a conjugate NNS donor set favors the coordination to metal ions. 
Regarding the role of a metal ion, it almost systematically increases the activity or 
contributes to mitigate the side effects of the organic parent compounds
11
. The reported 
effects related to their anticancer activity are ribonucleotide reductase (RR) inhibition, 
reactive oxygen species (ROS) production, topoisomerase II inhibition, mitochondria 
disruption and, more recently, a multidrug resistance protein (MDR1) inhibition
11
. 
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1.2  Biological targets 
1.2.1 Ribonucleotide Reductase 
During the Sixties French et al.
12
 formulated the hypothesis of the tridentate nature of α-
N-heterocyclic thiosemicarbazones giving an insight into the mode of action of this 
class of compounds. Thanks to the NNS chelating system they can bind metals with 
high formation constants. Based on this hypothesis Sartorelli et al.
11,13
 proposed as 
target of these compounds the enzyme ribonucleotide reductase after having observed 
that these molecules blocked the incorporation of 
3
H thymidine into DNA. 
Ribonucleotide reductase (RR) is an iron dependent enzyme which converts 
ribonucleotides to 2-deoxyribonucleotides through a mechanism generated by a tyrosil 
radical.  
Thelander
14
 observed that 1-formylisoquinoline thiosemicarbazone inhibits the enzyme 
by destroying the free radical. The mode of action of the quinoline derivative has been 
ascribed to the chelation of the iron contained in the enzyme and/or its possible 
activation of molecular oxygen in a redox process causing the destruction of the tyrosyl 
radical.  
Recently Kowol et al.
15
 studied iron(III) and gallium(III) complexes of Triapine
®
 and its 
related compounds with unsubstituted or dimethylated N4. Cytotoxicity assays were 
performed on two human cancer cell lines (41M and SK-BR-3). Complexation of 
Triapine
® 
and related ligands resulted in increased cytotoxicity of gallium(III) 
complexes while iron(III) derivatives showed reduced activity. On the contrary terminal 
nitrogen dimethylation was found to enhance the cytotoxicity of both metal complexes 
12 
 
and free ligands, unless a NH2 functionality was present anywhere at the 
thiosemicarbazone backbone. 
Tests on 
3
H-Cytidine DNA incorporation were performed on ribonucleotide reductase 
with Triapine
®
, with dimethyl thiosemicarbazone of formyl pyridine and their iron(III) 
to study an hypothetical relationship between growth and ribonucleotide reductase 
inhibition. Results showed that the toxicity on cells due to the dimethylated compounds 
was only partly dependent on the ribonucleotide reductase inhibition, thus implying that 
other mechanisms are involved. 
 
1.2.2 Topoisomerase II 
Topoisomerase-II is a family of enzymes which disentangle double stranded DNA 
introducing transient breaks
16
. Exploiting the fact that one of the mechanisms of action 
of naphthoquinone with anticancer properties is the stabilization of the cleavable 
complex formed between topoisomerase-II and DNA, Chen et al.
17
 synthesized 1,2-
naphthoquinone-2-thiosemicarbazone (Fig.1.8) and its metal complexes of copper(II), 
nickel(II) and palladium(II).  
 
 
 
Figure 1.8 - 1,2-naphthoquinone-2-thiosemicarbazone 
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These compounds were tested on MCF-7 cells of human breast cancer and compared 
with 1,2-naphthoquinone and etoposide, an anti-cancer agent known to inhibit 
topoisomerase-II. 
A comparison of cytotoxic activity of the compounds with 1,2- naphthoquinone showed 
a marked activity of the ligand and of its nickel and copper complexes while the 
palladium derivative had little effect. It is worth of note that the nickel complex is even 
more active than etoposide. 
Studies on topoisomerase-II to elucidate the mechanism of action of these compounds 
revealed that the metal complexes stabilize the cleavable complex between DNA and 
enzyme. Data also indicate that the three metal complexes antagonize the enzyme action 
on DNA because relaxed DNA formation is completely inhibited.  
 
1.2.3 Ros generators 
ROS (Reactive Oxygen Species), highly reactive molecules containing unpaired 
electrons, are the by-product of oxygen metabolism. Recently Hancock et al.
18
 
evaluated if the copper complex of NSC 689534 (Fig. 1.9) a derivative of formyl 
pyridine, could act as a ROS generator.  
 
 
Figure 1.9 – NSC 689534 
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This complex induces apoptosis in HL60 cells and causes a G2M block followed by 
necrosis in PC3 cells. Further tests revealed that these effects were caused as a direct 
consequence of ROS increase in a process which induces endoplasmic reticulum stress. 
To study the involvement of ROS, administration of the NSC-689534 copper complex 
in presence of different antioxidants, as N-acetyl-cysteine, ascorbate, diethylcarbamate 
(Cu/Zn superoxide dismutase inhibitor) or the antioxidant enzyme catalase, resulted in 
attenuated cytotoxic activity. As ROS can induce oxidative cleavages in DNA, Gomez-
Saiz
19
 studied the nuclease activity of formyl pyridine thiosemicarbazones. 
Electrophoresis of supercoiled DNA pUC18 exposed to the two metal complexes, in the 
presence of 1-mercaptopropionic acid (a reducing agent), was used to test their nuclease 
activity. Both complexes produce strand breaks. The use of radical scavengers, like 
DMSO, tert-butyl alcohol, sodium formate and potassium iodide, as control, inhibit the 
DNA cleavage suggesting that these compounds act as hydroxyl radical generator. 
 
1.2.4 MDR (Multidrug resistance) 
Multidrug resistance is a condition by which many cancers develop resistance to 
chemotherapy drugs
20
. This phenomenon is associated with a decrease of drug 
accumulation caused by the overexpression of ATP-binding cassette (ABC) transporter 
proteins, such as MDR-associated proteins (MRP), P-glycoprotein (P-gp) ABCB1 and 
ABCG2
21
. These proteins are transmembrane proteins which bind ATP to transport 
various molecules (ions, bile acids, organic anions) across biological membranes
22,23
. 
These proteins protect also organism from accumulation of toxic compounds conferring 
15 
 
cytotoxic resistance, in addition they play an important role in determining absorption, 
distribution,and excretion of many different pharmacologic compounds by the body
24
. 
Ludwig et al.
26
 identified a small thiosemicarbazone (NSC73306) (Fig.1.10) as a 
compound that exploits, rather than suppressing, P-gp function to induce cytotoxicity. 
 
 
 
Figure 1.10 - NSC73306 
 
NSC73306 was tested on four KB epidermoid carcinoma cell lines expressing 
increasing levels of P-gp. Results showed that the toxicity of NSC73306 is directly 
proportional to the levels of functional P-gp while no growth inhibition was observed in 
P-gp-negative cells when used at concentrations effective in P-gp-positive cells. It was 
also observed that a three-week exposure to NSC73306 caused a decrease of P-gp 
expression rendering cells sensitive to P-gp substrates against which they had 
previously shown resistance. This mechanism was further explained by Wu et al.
23
. As 
the presence of MRPs and ABCG2 is well documented in literature they investigated 
the interaction of NSC73306 with ABCG2, MRP1, MRP4 and MRP5. No particular 
cytotoxicity was observed in cells expressing these proteins compared with their 
respective parental cells but selectivity towards ABCG2 expressing cells was observed. 
16 
 
NSC73306 not only resulted possessing selectivity for the substrate-binding site of 
ABCG2 but it is also transported by it.  
Interaction between NSC73306 and ABCG2 was confirmed by an ATPase assay. 
In addition, NSC73306 at non toxic concentration (0.5 µmol/L) is able to resensitize 
ABCG2 expressing cells to topotecan and mitoxantrone, two antineoplastic agents. 
 
1.3 Perspectives 
As can be seen from the above paragraphs the way these molecules work is still greatly 
unknown since the amount of information we have is spread over a limited variety of 
compounds and a wide range of cell lines. The same compound inhibits proliferation of 
a particular tumor but leaves other totally unaffected. Recently, a thiosemicarbazone 
with an aliphatic long chain (citronellal), instead of the usual aromatic moiety that was 
held for necessary for the thiosemicarbazone to be active, has been tested on leukemia 
cell line U937 and revealed an activity of the same order of magnitude of many of those 
compounds previously published in the literature and this opens new perspectives in this 
research. 
In my doctoral work I followed three main research addresses that were carried out in 
parallel:  
1. A study of the relationship between structure and biological activity of variously 
functionalized thiosemicarbazones and their copper(II) and nickel(II) metal complexes, 
2. Theoretical studies, synthesis and biological evaluation of glycosylated 
thiosemicarbazones, 
17 
 
3. Quinoline and isatin thiosemicarbazone metal complexes as inhibitors of 
topoisomerase IIα. 
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Chapter 2 
Relationship between structure and biological activity of variously functionalized 
thiosemicarbazones and their copper(II) and nickel(II) metal complexes. 
 
2.1 Introduction 
Given the overwhelming but disorganized amount of information found in the literature 
I have decided to start from scratch and to plan a series of molecules with a common 
thiosemicarbazone core but possessing different characteristics. The parameters I chose 
for my research are: the influence of the aromatic/aliphatic nature of the 
aldehyde/ketone from which the thiosemicarbazone is synthesized, the overall 
hydrophobicity/hydrophilicity of the thiosemicarbazone modulated by adding on the 
terminal amino group hydrophilic fragments and the role of divalent metal ions of the 
first transition row (in particular copper(II) and nickel(II) for reasons explained below) 
and, as a starting point,  to focus my studies on the effects on a single cell line 
(leukemia cell line U937). The aldehydes chosen to prepare the basic 
thiosemicarbazones are citronellal, vanillin and pyridoxal (Fig. 2.1). 
 
 
 
Figure 2.1 – S-citronellal, vanillin and pyridoxal 
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The first two were chosen as representative of aliphatic and aromatic derivatives, while 
pyridoxal allows us to explore also the role of the chelation mode on the activity of 
these compounds since this thiosemicarbazone can bind as tridentate.  
Since the scarce water solubility is a notorious feature which afflicts thiosemicarbazone 
usage in biological media
1,2
, on the other extreme of the thiosemicarbazide fragment, on 
the amino nitrogen, other fragments have been added to tune the 
hydrophobicity/hydrophilicity of the whole molecule: N-ethylmorpholine and glucose. 
Glucose was chosen to give the molecule a marked hydrophilicity and also in the hope 
that the molecule could be possibly internalized through glucose transport proteins. This 
substituent, being highly polar, should also help cast light on a putative internalization 
mechanism that assigns to these thiosemicarbazones a role in the transport of metal ions 
through the cell membrane. According to this model, thiosemicarbazones would act by 
wrapping the metal ion with their polar heads and exposing the hydrophobic part to the 
exterior making these complexes prone to cross the hydrophobic lipid bilayer of the cell 
membrane. The presence of polar groups should prevent this mechanism. Of the first 
row divalent metals, copper(II) and nickel(II) have been chosen to evaluate the 
influence of a metal ion on the activity of the relative complexes. Zinc, cobalt and iron 
have been initially excluded based on previous experiences of inactivity of zinc and 
cobalt derivatives, due probably to their tendency to form tetrahedral and octahedral 
complexes, and because of the instability of iron(II) complexes. Unfortunately, due to 
their very limited solubility, formation constants of metal complexes with 
thiosemicarbazones are rarely found in the literature and the values reported are rather 
unreliable
3-5
 and copper(II) and nickel(II), according to the Irving Williams series, 
22 
 
should also possess, given a ligand, the highest formation constants that give us a 
certain confidence that the complexes do not dissociate into their constituents in water.  
Altogether nine compounds have been synthesized and for each of them also their 
copper(II) and nickel(II) complexes have been used for the biological tests. Eventually 
it has also been decided to carry out the preliminary biological tests on proliferation 
inhibition using cell line U937. This cell line was chosen because it was used for 
citronellal thiosemicarbazone studies that were carried out previously. 
 
2.2 Ligands 
The mentioned aldehydes were condensed with three thiosemicarbazides: 
thiosemicarbazide, N4-ethyl-thiosemicarbazide and N4-glycosyl thiosemicarbazide 
(Fig. 2.2) giving a total of nine ligands (Tab. 2.1).  
 
 
Figure 2.2 
 
The former two were commercially available while the latter was de novo synthesized 
using D-glucose as starting reagent. Tab. 2.1 summarizes the synthesized ligands and 
the acronyms used from here on. 
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 Citronellal Vanillin Pyridoxal 
 
 
 
 
CitrTSC 
 
 
    VanTSC 
 
PyrTSC 
 
 
 
 
 
 
CitrMor 
 
 
VanMor 
 
 
PyrMor 
 
 
 
 
 
CitrGlu 
 
 
VanGlu 
 
PyrGlu 
 
 
Table 2.1  
 
D-glucose was acetylated with pyridine and 4-dimethylaminopyridine in acetic 
anhydride and then halogenated with HBr 33% in dichloromethane under nitrogen 
atmosphere to obtain α-acetobromo-D-glucose (Fig. 2.3). 
 
 
 
Figure 2.3 – Synthesis of acetylated glucosyl thiosemicarbazide 
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In the presence of potassium thiocyanate and tetrabutyl ammonium chloride, following 
a SN2 mechanism, bromide was substituted with a isothiocyanate group
6
 giving the 
precursor of the thiosemicarbazide and its structure was determined by X-ray analysis 
(see experimental section). 
Glucosyl thiosemicarbazide was obtained as a white solid by dropping a solution of 
glucosyl isothiocyanate in ethanol into a cooled solution of  hydrated hydrazine in 
ethanol
7
. 
All the condensation reactions between the functionalized thiosemicarbazide and the 
selected aldehydes to obtain thiosemicarbazones were carried out refluxing for several 
hours the reagents in ethanol. Acetylated glucosyl thiosemicarbazones were then 
deprotected following the Zemplen procedure (MeONa/MeOH dry).  
 
2.2.1 Partition coefficient (P) 
Octanol/water partition coefficient (P) is the ratio between the concentration of a 
compound in octanol and its concentration in water (P = [analyte]Octanol/[analyte]Water). 
Partition coefficient is very used in pharmaceutical sciences to evaluate the distribution 
of a molecule in the two phases of a mixture of two immiscible solvents at equilibrium. 
Hence the partition coefficient is a measure of how hydrophilic or hydrophobic a 
chemical substance is. In medical practice, partition coefficients are useful for example 
in estimating distribution of drugs within the body.  
Drugs with partition coefficients > 2 are preferentially distributed to hydrophobic 
compartments such as lipid bilayers of cells while drugs with partition coefficients < 1.5 
preferentially are found in hydrophilic compartments such as blood serum. 
25 
 
 
Table 2.2 – Comparison between polarity (logP) of new thiosemicarbazones 
 
LogPs were calculated with ALOGPS 2.1 software
8
. The values reported in Tab. 2.2 
show that the ligands synthesized for the assays possess a wide variety of values that 
extend from 3.3 (maximum hydrophobicity) to -1.4 (minimum hydrophobicity). 
 
2.3  Complexes 
Copper(II) and nickel(II) complexes were obtained by refluxing an ethanol solution of 
the parent thiosemicarbazone to which the inorganic salts were added and the reaction 
products were separated by filtration. A few compounds were obtained in crystalline 
form by slow evaporation of the reaction solvent. The complexes were characterized by 
elemental analysis, ES-MS, X-ray diffraction. 
 
2.4 Biological assays 
U937 cells were grown until a concentration of 20x10
4
/mL was reached. 
Thiosemicarbazones and their metal complexes were then administered at different 
 logP  logP  logP 
CitrTSC 3.3 CitrMor 3.2 CitrGlu 1.5 
PyrTSC 1.2 PyrMor 1.2 PyrGlu -0.5 
VanTSC 0.2 VanMor 0.2 VanGlu -1.4 
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concentrations (1 up to 100 µM) to establish the maximum concentration necessary to 
inhibit, after 24 h, cellular proliferation by 50%.  
To evaluate inhibition, a colorimetric assay (XTT) was performed using ProCheck™ 
cell viability assay (Itergen). This technique is based on the spectrophotometric 
revelation of the cellular reduction of a tetrazole (2,3-bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide) to a formazan (Fig. 2.4). 
 
 
 
Figure 2.4 – Reduction of tetrazole to formazan 
 
After treatment with the compounds, cells were distributed in a volume of 100 µL in a 
microtiter plate with 96 plates, then 20 µL of reagent cell viability ProCheck™ were 
added to a final volume of 120 µL. After 1 – 4 hours of incubation optical density was 
measured with ELX800 (Packard) spectrophotometer, in this way information about cell 
vitality are gained and it is possible to determine the maximum concentration necessary 
to inhibit cellular proliferation by 50% (IC50). Once determined the IC50 value further 
experiments were carried out to determine cellular vitality after an incubation of 24h 
using Trypan blue to colour dead cells and a hemocytometer to count cells. 
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2.4.1 Cell growth inhibition of ligands and complexes  
All the ligands have shown no significant antiproliferative activity on cell line U937, at 
least up to 100 µM, with the exception of CitrGlu that shows a 40% inhibition at 
100µM. Differently from the ligands, most of their metal complexes possess remarkable 
activity. From Tab. 2.3 it is apparent that copper derivatives are more active than those 
of nickel but while the non substituted thiosemicarbazones present activities of the same 
order of magnitude we observe remarkably low GI50 values for the ethylmorpholine 
copper derivatives. The most striking difference is observable between the copper 
glucosylated thiosemicarbazones for which the GI50 values pass from a 18 µM for the 
citronellal derivative to a >50 µM for the vanillin and the pyridoxal thiosemicarbazone 
derivatives.  
 
 
Table 2.3 - GI50 of Cu and Ni of citronellal, vanillin and pyridoxal thiosemicarbazonates  
 
 Complexes GI50 (µM) Complex GI50 (µM) Complex GI50 (µM) 
Tsc Cu(CitrTSC)2 14.7 Cu(VanTSC)2 17 Cu(PyrTSC)Cl2 14.4 
Ni(CitrTSC)2 10 Ni(VanTSC)2 40 Ni(PyrTSC)Cl2 - 
Mor Cu(CitrMor)2 6.3 Cu(VanMor)2 9 Cu(PyrMor)Cl2 - 
Ni(CitrMor)2 7.8 Ni(VanMor)2 19.5 Ni(PyrMor)Cl2 - 
Glu Cu(CitrGlu)2 18 Cu(VanGlu)2 >50 Cu(PyrGlu)Cl2 83 
Ni(CitrGlu)2 44 Ni(VanGlu)2 >50 Ni(PyrGlu)Cl2 >100 
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Besides testing the antiproliferative activity on cell lines U937 (histiocytic lymphoma) it 
has also been possible to extend the biological assays to cell line HT-29 (colon 
carcinoma). As an antiproliferative reference substance has been used cis-platin. 
According to the NCI (National Cancer Institute) approach for the “60 human tumor 
cell line anticancer drug screen” (NCI60), growth inhibiting concentrations at 50% 
(GI50, 50 % Growth Inhibition), growth inhibiting at 100% (TGI, Total Growth 
Inhibition) and lethal at 50% of the cells (LC50, 50 % Lethal Concentration) have been 
determined. Evaluation has been carried out on a wide range of concentrations (0.5 ÷ 
50µM). 
All citronellal and vanillin ligands present no antiproliferative activity up to a 
concentration of 50µM. From the reported tables (Tab.2.4 and Tab.2.5) it is apparent 
that this activity is strongly influenced by metal complexation. 
In particular, compounds with GI50<20 µM on cell line U937 are nickel (II) complexes 
of CitrTSC, CitrMor, VanMor (Ni(CitrTSC)2, Ni(CitrMor)2, Ni(VanMor)2) and 
copper(II) complexes of CitrTSC, CitrGlu, CitrMor, VanTSC and VanMor 
(Cu(CitrTSC)2, Cu(CitrGlu)2, Cu(CitrMor)2, Cu(VanTSC)2, Cu(VanMor)2). Among 
them the only complexes of Cu (II) having a GI50<20µM on cell line HT29 are 
Cu(CitrTSC)2 and Cu(CitrMor)2. The glycosylation of the ligand seems to reduce the 
antiproliferative activity.  
 
 
 
 
29 
 
U937 
Compound GI50 (µM) TGI (µM) LC50 (µM) 
CitrTSC >50 > 50 > 50 
Ni(CitrTSC)2 10 50 > 50 
Cu(CitrTSC)2 14,7 > 50 > 50 
CitrGlu >50 > 50 > 50 
Ni(CitrGlu)2 44 > 50 > 50 
Cu(CitrGlu)2 18 38 > 50 
CitrMor >50 > 50 > 50 
Ni(CitrMor)2 7,8 20 39,5 
Cu(CitrMor)2 6,3 8,2 10 
VanTSC > 50 > 50 > 50 
Ni(VanTSC)2 40 > 50 > 50 
Cu(VanTSC)2 17 40,5 > 50 
VanGlu > 50 > 50 > 50 
Ni(VanGlu)2 > 50 > 50 > 50 
Cu(VanGlu)2 > 50 > 50 > 50 
VanMor > 50 > 50 > 50 
Ni(VanMor)2 19,5 50 > 50 
Cu(VanMor)2 9 35 > 50 
 
Table 2.4 – Ligand and complex concentrations inhibiting growth at 50% (GI50, 50 % 
Growth Inhibition), growth at 100% (TGI, Total Growth Inhibition) and lethal at 50% 
(LC50, 50 % Lethal Concentration) for cell line U937 (histiocytic lymphoma). 
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HT-29 
Compound GI50 (µM) TGI (µM) LC50 (µM) 
CitrTSC 
>50 > 50 > 50 
Ni(CitrTSC)2 47 > 50 > 50 
Cu(CitrTSC)2 10 24,5 40,5 
CitrGlu 
>50 > 50 > 50 
Ni(CitrGlu)2 >50 > 50 > 50 
Cu(CitrGlu)2 >50 > 50 > 50 
CitrMor 
>50 > 50 > 50 
Ni(CitrMor)2 >50 > 50 > 50 
Cu(CitrMor)2 7,5 20,5 37 
VanTSC 
>50 > 50 > 50 
Ni(VanTSC)2 >50 > 50 > 50 
Cu(VanTSC)2 >50 > 50 > 50 
VanGlu 
>50 > 50 > 50 
Ni(VanGlu)2 >50 > 50 > 50 
Cu(VanGlu)2 >50 > 50 > 50 
VanMor 
>50 > 50 > 50 
Ni(VanMor)2 >50 > 50 > 50 
Cu(VanMor)2 34 > 50 > 50 
 
Table 2.5 – Ligand and complex concentrations inhibiting growth at 50% (GI50, 50 % 
Growth Inhibition), growth at 100% (TGI, Total Growth Inhibition) and lethal at 50% 
(LC50, 50 % Lethal Concentration) for cell line HT29 (colon carcinoma). 
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Histosensibility has been tested for two of the molecules that from a first screening 
resulted to be the most active: complex Ni(CitrTSC)2 and complex Cu(CitrMor)2. 
Cells deriving from hematological and CNS (central nervous system) tumors seem to be 
more sensitive to the nickel complex. These cells present a GI50 generally lower than 
10µM. In particular this complex induces a strong cytotoxic affect (LC50) at 
concentrations lower than 50 µM only on U266 lines (multiple myeloma), SH-SY5Y 
and SK-N-MC (CNS). The most resistant lines (IG50>40µM) are from colon (HT-29), 
prostate (PC-3), skin (A-375) and connective tissue (HT-1080) (Fig. 2.6). 
 
Figure 2.6 – Histosensitivity to complex Ni(CitrTSC)2 of the analyzed cell lines. In red 
are represented the most sensitive lines, in blue the less sensitive. 
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All tested cell lines have shown a mild sensitivity to complex Cu(CitrMor)2 with a 
GI50<10µM, a strong cytotoxic effect (LC50) at concentrations lower than 10µM has 
been observed on cell lines U937 and Jurkat. Cell lines Hela(cervix cancer); Jurkat 
(leukemia) and SK-N-MC (CNS) (Fig. 2.7). 
 
 
 
Figure 2.7 – Histosensitivity to complex Cu(CitrMor)2 of the analyzed cell lines. In red 
the more sensitive lines, in blue the less sensitive. 
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2.5 Conclusions 
New thiosemicarbazones were synthesized with the aim to study how substituent groups 
in position N4 and coordination to copper(II) and nickel(II) influence their biological 
activity. The free ligands do not show significant biological activity independently from 
the presence of a substituent on N4. On the contrary, metal complexes show marked 
biological activity. Copper complexes present a general higher proliferation inhibition 
activity. In particular the copper complexes with the morpholine derivatives present 
higher activities than the non-substituted and the glycosylated thiosemicarbazones. 
Worth of note is that morpholine ligands are those with the partition coefficient closer 
to the values required for an effective lipid membrane crossing and this would confer 
them an easier way to diffuse into the cytoplasm. Nevertheless subsequent biological 
studies (unpublished results) have revealed that their activity is not proportional to the 
concentration as it is to be expected if the limiting process were diffusion.  
The activity of vanillin and citronellal thiosemicarbazones was then extended to cell line 
HT-29 (colon carcinoma).  Also in this case citronellal and vanillin ligands present no 
antiproliferative activity up to a concentration of 50µM and also in this case the 
glycosylation of the ligand seems to reduce the antiproliferative activity. 
Histosensibility has been tested for two of the molecules that from a first screening 
resulted to be the most active:  Ni(CitrTSC)2 and Cu(CitrMor)2. Cells deriving from 
hematological and CNS (central nervous system) tumors seem to be more sensitive to 
the nickel complex. In particular this complex induces a strong cytotoxic affect (LC50) 
at concentrations lower than 50 µM only on U266 lines (multiple myeloma), SH-SY5Y 
and SK-N-MC (CNS).  
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All tested cell lines have shown a mild sensitivity to complex Cu(CitrMor)2 with a 
GI50<10µM, a strong cytotoxic effect (LC50) at concentrations lower than 10µM has 
been observed on cell lines Hela(cervix cancer), Jurkat (leukemia) and SK-N-MC 
(CNS). 
 
2.6 Experimental 
Dry methanol were prepared according to standard procedures and stored over 
molecular sieves. TLC were performed on Silica gel Merck 60 F254 aluminium sheets. 
Flash chromatography was performed on MP Silica 63-200 mesh 60Å (EchoChrom™), 
1H and NMR spectra were recorded on Bruker 300 Avance and Bruker 400 Avance 
spectrometers, at 300 K. The reported J values are referred to H,H coupling constants. 
Chemical shifts are reported as δ values in ppm using the solvent residual peak as 
internal standard. Elemental analysis were recorded on Flash 1112 Series Analyser (CE 
Instruments) Mass spectra by electrospray ionization (ESI) methods were recorded on 
LTQ ORBITRAP XL Thermo. 
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2.6.1 Synthesis of the ligands 
[CitrTSC] 
(S-citronellal thiosemicarbazone) 
 
 
 
A solution of S-citronellal (0.40 mL, 2.22 mmol) and thiosemicarbazide (0.21 g, 2.22 
mmol) in EtOH (10 mL) was refluxed for 60 min under stirring, the mixture was then 
cooled and the product was isolated as a white powder. 
Yield : 95% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 9.05 (s, 1H, NH), 7.27 (t, 1H,  J = 6.0 Hz, 
CH=N), 7.08 (2br s, 1H each, NH), 5.04 (m, 1H, CH=C(CH3)2), 2.20 (2m, 2H, 
CH2CHCH3), 1.94 (m, 2H,  CH2CH=C(CH3)2), 1.76 (m, 1H, CH2CHCH3), 1.64 and 
1.56 (2s, 6H, 3H each, CH(CH3)2), 1.34 (m, 1H, CH2CHCH3), 1.34  - 1.28 (2m, 2H, 1H 
each, CH3CHCH2CH2), 0.94 (3H, d, J = 7.0, CHCH3).  
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[CitrMor] 
(S-citronellal-4-[2-(4-morpholinyl)ethyl]-3-thiosemicarbazone) 
 
 
 
A solution of S-citronellal (0.35 mL, 1.95 mmol) in EtOH 95%  (10 mL) was added to a 
stirred solution of N4 ethyl morpholine thiosemicarbazide (398 mg, 1.95 mmol) in 
EtOH 95% (10 mL). 
The mixture was refluxed until TLC (AcOEt/C6H12 1:3) revealed starting material 
consumption. 
After concentration under reduced pressure a pale yellow oil was obtained. 
Yield: 96% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 8.78 (s, 1H, CH2NHC=S), 7.88 (bs, 1H, 
NHN=C), 7.15 (t, 1H, CH=N), 5.04 (m, 1H, CH=C(CH3)2), 3.74 (2m, 4H, OCH2CH2N 
+ CH2NHCS), 2.65 (t, 2H, OCH2CH2N), 2.52 (m, 2H, NHCH2CH2NMor), 2.27 (m, 1H,  
C3H2, H-a), 2.0 (m, 4H, OCH2CH2N,), 1.94 (m, 2H, CH2CH=C(CH3)2), 1.76 (m, 1H, 
CH2CHCH3), 1.70 and 1.62 (2s, 6H, 3H each, CH(CH3)2), 1.4  - 1.25 (2m, 2H, 1H each, 
CH3CHCH2CH2), 0.94 (d, 3H, J = 7.0, CHCH3). 
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[VanTSC]  
(Vanillin thiosemicarbazone) 
 
 
 
A stirred solution of vanillin (0.2 g, 1.31 mmol) and thiosemicarbazide (0.11 g, 1.31 
mmol)  in EtOH (20 mL) was refluxed. After 60 min under stirring at reflux 
temperature, the mixture was cooled and by slow solvent evaporation the product was 
isolated as yellow crystals 
Yield: 92% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 11.38 (s, 1H, NHN), 9.72 (s, 2H, NH2), 7.96 (s, 
1H, CH=N), 7.33 (d, J = 1.59 Hz, 1H, H5van), 7.13 (dd, J = 8.20, 1.59 Hz, 1H, H2van), 
6.81 (d, J = 8.20 Hz, 1H, H3van), 3.83 (s, 3H, OCH3). 
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[VanMor]  
(Vanillin-4-[2-(4-morpholinyl)ethyl]-3-thiosemicarbazone) 
 
 
A stirred solution of vanillin (0.20 g, 1.31 mmol) and N4 ethyl morpholine 
thiosemicarbazide (0.26 g, 1.31 mmol)  in EtOH (15 mL) was refluxed. After 3 h the 
mixture was poured into a crystallizer and the solvent was slowly evaporated to obtain 
the product as white crystals. 
Yield: 90% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 11.38 (s, 1H, NHN), 8.29 (t, J = 5.29 Hz, 1H, 
NH), 7.96 (s, 1H, CH=N), 7.33 (d, J = 1.59 Hz, 1H, H5van), 7.13 (dd, J = 8.20, 1.59 Hz, 
1H, H2van), 6.81 (d, J = 8.20 Hz, 1H, H3van), 3.83 (s, 3H, OCH3), 3.68 (m, 2H, 
CH2NH), 3.56 (t, 2H, OCH2CH2N), 2.51 (t, J = 4.84 Hz, 1H, CH2 CH2NH), 2.44 (m, 
2H, OCH2CH2N) 
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Figure 2.5. ORTEP drawing of VanMor (50% probability plot). 
 
The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using ORTEPIII. Crystallographic data: C15H22N4O3S1, Mr = 338., triclinic, 
space group P-1, a = 7.051(2) , b = 8.119(2), c= 15.798(4) Å, α =82.014(3), β = 
79.889(3), γ = 86.463(4)°; V = 881.1(4)Å3, Z = 2, ρcalc = 1.276 Mgm–3, T = 298.15 K, 
F(000) = 210, crystal size = 0.50x0.40x0.30 mm, index range = –9 < h < 9, –10 < k < 
10, –20 < l < 20, collected reflections = 11561, unique reflections = 4037, refined 
parameters = 208, goodness-of-fit = 1.043, final R factor = 0.0407, wR2 = 0.1235, 
electronic density residues = 0.19 and –0.16 eÅ–3. 
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[PyrTSC]  
(Pyridoxal thiosemicarbazone) 
 
 
 
A stirred solution of pyridoxal (0.2 g, 1.31 mmol) and thiosemicarbazide (0.11 g, 1.31 
mmol)  in EtOH (10 mL) was refluxed. After 2 h under stirring at reflux temperature, 
the mixture was cooled and the product was isolated as a yellow powder.  
Yield: 92% 
 
1
H NMR (300MHz, DMSO-d6): δH ppm 11.60 (br s, 1 H, NH), 9.65 (br s, 1H, OH), 
8.57 (s, 3H, CHNpy + NH2), 7.99 (s, 1H, CHN), 5.25 (s, 1H, OH), 4.57 (s, 2H, CH2O), 
1.76 (s, 3H, CH3). 
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[PyrMor]  
(Pyridoxal-4-[2-(4-morpholinyl)ethyl]-3-thiosemicarbazone) 
 
 
 
A stirred solution of pyridoxal (0.40 g, 2.39 mmol) and thiosemicarbazide (0.48 g, 2.39 
mmol) in EtOH (30 mL) was refluxed. During the reflux a precipitate appeared and 
after 3 h the solution was filtered and the product collected. 
Yield: 90% 
 
1
H NMR (300 MHz, DMSO-d6) : δH ppm 11.72 (br s, OH), 8.58 (s, 1H, CHpyr), 8.30 
(br m, 1H, NH), 8.01 (s, 1H, HC=N), 5.27 (t, J = 5.32 Hz, 1H, CH2OH), 4.61 (d, J = 
5.00 Hz, 1H, CH2OH), 3.68 (m, 1H, CH2NH), 3.64-3.59 (m, 1H,CH2CH2O), 2.53 (t, J = 
4.71 Hz, 1H,CH2N), 2.44 (m, 1H, CH2Nmor), 2.41 (s, 3H, CH3). 
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[GluOAc] 
Glucose pentaacetate 
 
 
 
To a round flask containing D-glucose (1g, 9.24 mmol) in AcO2 (7 mL) were added 
pyridine (7mL) and a small amount of 4- dimethylaminopyridine. The solution was 
stirred in an ice-cold bath for 5h and than at room temperature for 18h. Dichlorometane 
(20mL) and water (20mL) were added to the solution, the organic phase was then 
separated and consecutively washed with a sat. aq. CuSO4 until the dark blue color 
disappeared and then with water (20mL). Then dried over Na2SO4 and concentrated 
under reduced pressure to give an oil which crystallizes. 
Yield: 93%  
 
1
H NMR (300MHz, CDCl3): δH (ppm) 6.34 (d, J = 3.68 Hz, H-1), 5.47 (t, J = 10.30, 1H, 
H-3),  5.15 (m, 1H, H-4), 5.10 (dd, J = 10.30, 3.68 Hz, 1H, H-2), 4.28 (dd, J = 12.58, 
4.22 Hz, 1H, H-7), 4.11 (m, 2H H-5, H-6), 2.18 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.04 
(s, 3H, OAc), 2.03 (s, 3H, OAc), 2.02 (s, 3H, OAc). 
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[GluOAcBr] 
Acetobromo-α-D-glucose 
 
 
 
HBr in acetic acid (33%) was added dropwise to a solution of pentaacetylglucose (1 gr, 
2.56 mmol) in dichloromethane (5 mL) under nitrogen atmosphere. The reaction 
mixture was stirred at room temperature for 2h, then ice-cold water (10 mL) was added 
and the mixture was extracted with CH2Cl2 (3·20 mL). The combined CH2Cl2 layers 
were washed with a saturated NaHCO3 solution, H2O, and brine, and the filtrate was 
evaporated in vacuo to give a thick oil which crystallizes.  
Yield:  95% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 6.63 (d, J = 4.00 Hz, 1H, H-1), 5.58 (t, J = 9.72 
Hz, 1H, H-3), 5.18 (t, J = 9.85 Hz, H-4), 4.85 (dd, J = 9.99, 4.05 Hz, 1H, H-2), 4.39-
4.27 (m, 1H, H-5), 4.13 (m, 2H, H-6), 2.08 (4s, 12H, OAc) 
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[GluOAcNCS] 
2,3,4,6-Tetra-O-acetyl-β-D-glucose isothiocyanate 
 
 
 
A mixture of potassium thiocyanate (0.200 g, 2 mmol), tetrabutylammonium chloride 
(0.285 g, 1 mmol) and molecular sieves (4Å, 1,5 g) in acetonitrile is stirred at room 
temperature for 3 h. Then acetobromo-α-D-glucose (0.423 g, 1 mmol) is added and the 
mixture refluxed until the reaction is complete as detected by TLC (AcOEt/ C6H12 2:3). 
Then solution is filtered and concentrated under pressure to afford a residue, which is 
purified by flash chromatography (silica gel, AcOEt/ C6H12 2:3). 
Yield : 80% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 5.13 (m, 4H, H-1, H-2, H-3, H-4), 4.27 (dd, J = 
12.45, 4.66 Hz, 1H, H-6), 4.17 (dd, J = 12.45, 2.27 Hz, 1H, H-6), 3.77 (ddd, J = 10.14, 
4.66, 2.27 Hz, 1H, H-5), 2.13-2.05 (4s, 12H, OAc) 
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Figure 2.6. ORTEP drawing of 2,3,4,6-tetra-O-acetyl-β-D-glucose isothiocyanate ( 50% 
probability plot). 
 
The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using  ORTEPIII. Crystallographic data:  C15H19N1O9S1, Mr = 389.37, 
orthorhombic, space group P212121,  a =5.543(1), b =14.113(2), c =25.078(4)Å, V = 
1961.8(5)Å
3, Z = 4, ρcalc = 1.318 Mgm–3,  T = 298.15 K, F(000) = 816, crystal size = 
0.40x0.30x0.30 mm, index range  =  –6 < h < 6, –17 < k < 16, –31 < l < 23, collected 
reflections = 11673, unique reflections = 3939, refined parameters = 255, goodness-of-
fit = 0.952, final R factor = 0.0739, wR2 = 0.2415, electronic density residues = 0.51 
and –0.47 eÅ–3. 
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[GluOAcTSC] 
2,3,4,6-Tetra-O-aceto-β-D-glucose thiosemicarbazide 
 
 
 
To a stirred solution of hydrazine monohydrate (86 μL, 1.76 mmol) in EtOH (25 mL) at 
0
°
C, a solution of 2,3,4,6-tetra-O-acetyl-β-D-glucose isothiocyanate (0.67 g, 1.73mmol) 
in EtOH (40 mL)was slowly added dropwise. During the addition a white precipitate 
appeared. After the addition the solution was stirred for additional 5’ and the precipitate 
was collected by filtration. 
Yield: 76% 
 
1
H NMR (300MHz, d6DMSO): δH (ppm) 9.28 (s, 1H, NHC=S), 8.20 (s, 1H, NHNH2), 
5.78 (t, J = 9.35 Hz, 1H, H-1), 5.39 (t, J = 9.35 Hz, 1H, H-3), 5.11 (t, J = 9.35 Hz, 1H, 
H-2), 5.09 (t, J = 9.35 Hz, 1H, H-4), 4.33 (dd, J = 12.42, 4.41 Hz, 1H, H-6), 4.14 (dd, J 
= 12.42, 2.07 Hz, 1H, H-6), 3.89 (ddd, J = 9.35, 4.41, 2.07 Hz, 1H, H-5), 2.00 (m, 12H, 
OAc). 
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[CitrGluOAc] 
(1-S-Citronellal-4-(2,3,4,6-tetra-O-aceto-β-D-glucosyl)-3-thiosemicarbazone) 
 
 
 
A stirred solution of citronellal (0.26 mL, 1.48 mmol) and glucosyl-thiosemicarbazide 
(0.62 g, 1.48 mmol) in EtOH (25 mL) was refluxed. After 24 min under stirring at 
reflux temperature, the mixture was cooled, the solution concentrated under reduced 
pressure and the product purified by flash chromatography (AcOEt/C6H12 1:3). 
Yield: 86% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 8.86 (s, 1H, NH), 7.13 (t, J = 8.39 Hz, 1H, 
HC=N), 5.95 (t, J = 8.89 Hz, 1H, H-1) , 5.38 (t, J = 9.37 Hz, 1H, H-3), 5.15-5.02 (m, 
2H, H-2, H-4) H4,2 , 4.33 - 4,03 (m, 2H, H-6, H-6’),  3.87 (m, 1H, H-5), 2.17 (m, 1H, 
CH2CHN), 2.02 - 1.98 (m, 12H, OAc), 1.7 (m, 1H CHCH3), 1.65 – 1.57 (2s, 6H, 
(CH3)2C=), 1.23 (m, 1H, CH2CHCH3), 0.9 (d, 3H, CHCH3) 
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[CitrGlu] 
(1-S-Citronellal-4-(β-D-glucosyl)-3-thiosemicarbazone) 
 
 
 
A solution of CitrGluOAc (0.37g, 2.35mmol) in dry methanol (50 mL) was heated to 
50°C in a schlenck tube for 8 h in presence of a catalytic quantity of sodium methoxyde. 
Neutralization of the methoxyde by Dowex 50WX4 acid ion-exchange resin, followed 
by filtration and evaporation of the filtrate afforded a pure material by 
1
H NMR. 
Yield: 98% 
  
1
H NMR (300MHz, CDCl3): δH (ppm) 8.46 (s, 1H, NH) , 8.06 (d, J = 8.76 Hz, 1H, 
NH), 7.46 (t, J = 5.84 Hz, 1H, HC=N), 5.27 (t, J = 8,74 Hz, 1H, H-1), 5,08 (t, J = 7.01 
Hz, 1H, HC=C(CH3)2) 3.70-3.00 (m, 6H, H-2, H-3, H-4, H-5, H-6, H-6’), 2.23 – 2.05 
(2m, 1H, CH2CHN),1.97 (m, 1H, CH2CH=C) 1.64 (m, 1H, CHCH3)1.64 – 1.57 (2s, 6H, 
(CH3)2C=), 1.21 (m, 1H, CH2CHCH3), 0.88 (d, 3H, CHCH3) 
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[VanGluOAc] 
(1-Vanillin-4-(2,3,4,6-tetra-O-aceto-β-D-glucosyl)-3-thiosemicarbazone) 
 
 
 
A solution of glucosylthiosemicarbazide (1 g, 2.35 mmol) and vanillin (0.37g, 
2.35mmol) in ethanol (50 mL) was refluxed for 12 h. Then the solution was cooled to 
room temperature concentrated under reduced pressure and purified by flash 
chromatography (AcOEt/C6H12 2:3). 
Yield: 81% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 9.88 (s, 1H, NH), 8.37 (d, J = 8.45 Hz, 1H, 
HC=N), 7.75 (s, 1H, NH), 7.52 (m, 1H, Hvan), 7.03 (dd, J = 8.14, 1.63 Hz, 1H, 
CHvan), 6.93 (d, J = 8.10 Hz, 1H, CHvan), 5.67 (t, J = 8.95 Hz, 1H, H-1), 5.44 (t, J = 
9.49 Hz, 1H, H-3), 5.18 (td, J = 11.91, 9.58 Hz, 2H, H-2, H-4,), 4.43-4,15 (m, 2H, H-6, 
H-7), 4.04 (s, 3H, CH3), 3.95 (m, 1H, H-5), 2,2-2,0 (m, 12H, OAc). 
 
50 
 
 
Figure 2.7. ORTEP drawing of VanGluOAc ( 50% probability plot). 
 
The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using  ORTEPIII. Crystallographic data:  C23H29N3O11S1, Mr = 553.54, 
orthorhombic, space group P212121, a = 9.015 (2), b = 15.221(3), c = 19.882(4)Å, V = 
2728.2(10)Å
3, Z = 4, ρcalc = 1.353 Mgm–3,  T = 298.15 K, F(000) = 1168, crystal size = 
0.60x0.40x0.20 mm, index range  =  –11 < h < 11, –18 < k < 19, –25 < l < 19, collected 
reflections= 16954, collected reflections = 6297, refined parameters = 343, goodness-of-
fit = 0.856, final R index = 0.0418, wR2 = 0.0898, electronic density residues = 0.25 
and –0.16 eÅ–3. 
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[VanGlu] 
(1-Vanillin-4-(β-D-glucosyl)-3-thiosemicarbazone) 
 
 
 
A solution VanGluOAc (0.37g, 2.35mmol) in dry methanol (50 mL) was refluxed for 8 
h in the presence of a catalytic quantity of sodium methoxyde. Neutralization of the 
methoxyde by Dowex 50WX4 acid ion-exchange resin, followed by filtration and 
evaporation of the filtrate afforded a pure material by 
1
H NMR. 
Yield: 98% 
 
1
H NMR (300MHz, D2O): δH (ppm) 8.50 (s, 1H, NH), 8.25 (d, J = 9.11 Hz, 1H, NH), 
7.92 (s, 1H, CHN), 7.22 (d, J = 1.57 Hz, 1H, CHvan), 6.97 (dd, J = 8.24, 1.71 Hz, 1H, 
CHvan), 6.51 (d, J = 8.19 Hz, 1H CHvan), 5.36 (t, J = 9.07 Hz, 1H, H-1), 3.76 (s, 3H, 
OCH3), 3.70-3.00 (m, 6H, H-2-6). 
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[PyrGluOAc] 
(1-(Pyridoxal)-4-(2,3,4,6-tetra-O-aceto-β-D-glucosyl)-3-thiosemicarbazone) 
 
 
 
A solution of tetra-acetyl glucosylthiosemicarbazide (1 g, 2.3 mmol) and pyridoxal 
(0.39g, 2.3 mmol) in ethanol (50 mL) was refluxed for 12 h. Then the solution was 
cooled to r.t. concentrated under reduced pressure and purified by flash chromatography 
(AcOEt/C6H12 10:1). 
Yield: 81% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 8.61 (s, 1H, CHpyr), 7.99 (s, 1H, HC=N), 5.98 
(t, J = 9.13 Hz, 1H, H-1), 5.41 (t, J = 9.50 Hz, 1H, H-3), 5.31 (t, J = 5.30 Hz, 1H, H-2), 
5.22 (d, J = 8,96 Hz, 1H, NH), 4.96 (t, J = 9.75 Hz, 1H, H-4), 4.58 (d, J = 5.26 Hz, 1H, 
CH2Pyr),  4.11 (d, J = 9.99 Hz, 1H, H-5), 4.15 (m, 2H, H-6, H-7), 2.42 (s, 1H, CH3), 
2.01-1.91 (m, 12H, OAc) 
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[PyrGlu] 
(1-Pyridoxal-4-(β-D-glucosyl)-3-thiosemicarbazone) 
 
 
 
A solution of PyrGluOAc (0.37g, 2.35mmol) in dry methanol (50 mL) was refluxed for 
8 h in the presence of a catalytic quantity of sodium methoxyde. Neutralization of the 
methoxyde by Dowex 50WX4 acid ion-exchange resin, followed by filtration and 
evaporation of the filtrate afforded a pure material by 
1
H NMR. 
Yield: 97% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 8.48 (s, 1H, NH), 7.89 (d, J = 9.32 Hz, 1H, NH), 
7.48 (s, 1H, CHpyr), 7.24 (s, 1H, HC=N), 5.41-5.19 (m, 1H, H-1), 4.55 (s, 1H, 
CH2OH), 3.70-3.00 (m, 6H, H-2, H-3, H-4, H-5, H-6, H-6’) 2.37 (s, 3H, CH3). 
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2.6.2 Synthesis of the complexes 
[Cu(CitrTSC)2] 
 
A solution of Cu(OAc)2·H2O (0.05 mg, 0.25 mmol) in H2O (10 mL) was added 
dropwise to a solution of CitrTSC (0.11 g, 0.5 mmol) in EtOH (20 mL), at room 
temperature. The complex was isolated as dark red solid by slow solvent evaporation. 
Yield: 90% 
 
Elem. An. C22H40CuN6S2: C, 51.68%; H, 7.88%; N, 16.42%; S, 12.53%. Found: C, 
51.70%; H, 7.89%; N, 16.42%; S, 12.53% 
 
[Ni(CitrTSC)2] 
 
A solution of Ni(OAc)2·4H2O (0. mg, 0.044 mmol) in H2O (10 mL) was added 
dropwise to a solution of CitrTSC (19.98 mg, 0.088 mmol) in EtOH (20 mL), at room 
temperature. The complex was isolated as dark green crystals suitable for X-ray 
crystallography. 
Yield: 92% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 6.81 (t, 1H, J = 6.0, C2H), 6.20 and 6.17 (2s, 2H, 
1H each, N1H2), 5.14 (m, 1H, C7H), 2.07 (m, 2H,3H2), 1.93 (m, 2H, C6H2), 1.65 and 
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1.61 (2s, 6H, 3H each, C9H3 and C10H3), 1.31 (m, 1H, C4H), 1.22 (m, 2H, C5H2), 
0.90 (d, 3H,J = 7.0, C11H3) 
Elem. An. C22H40N6NiS2: C, 51.68%; H, 7.88%; N, 16.42%; S, 12.53%. Found: C, 
51.60%; H, 7.82%; N, 16.57%; S, 12.58% 
 
[Cu(CitrMor)2] 
 
To a solution of ligand CitrMor (0.40 g, 0.13 mmol) in EtOH (50 mL), at room 
temperature with stirring, was added Cu(OAc)2·H2O (0.13 g, 0.06 mmol). The resulting 
clear solution reddish first and brown after a while was left at room temperature and 
stirred for one hour. The complex was isolated as dark red crystals suitable for X-ray 
crystallography after slow evaporation of the solvent.  
Yield: 90% 
 
Elem. An. C22H40CuN6S2: C, 51.67%; H, 7.88%; N, 16.43%; S, 12.54%. Found:C, 
51.60%; H, 7.81%; N, 16.58%; S, 12.59%. 
 
[Ni(CitrMor)2] 
 
To a solution of ligand CitrMor (0.40 g, 0.11 mmol) in EtOH (50 mL), at room 
temperature with stirring, solid Ni(OAc)2·4H2O (0.10 g, 0.05 mmol) was added. The 
resulting clear reddish first and brown after a while, was left at room temperature and 
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stirred for one hour. The complex was isolated as green crystals suitable for X-ray 
crystallography after slow evaporation of the solvent. 
Yield: 90% 
 
1
H NMR (300MHz, CDCl3): δH (ppm) 6.85 (t, 1H, CH=N), 5.39 (bs, 1H, CH2NHCS), 
5.08 (m, 1H, CH=C(CH3)2), 3.74 (m, 4H,  OCH2CH2N + CH2NHCS), 3.31 (t, 2H, 
NCH2CH2NH), 2.52 (m, 2H, NHCH2CH2NMor), 2.45 (t, 2H, NCH2CH2NH), 2.31 (m, 
4H, OCH2CH2N,), 1.94 (2H, m, CH2CH=C(CH3)2), 1.60 (1H, m, CH2CHCH3), 1.70 and 
1.62 (6H, 2s, 3H each, CH(CH3)2), 1.4-1.2 (m, 2H, CH3CHCH2CH2), 0.92 (d, 3H, 
CHCH3). 
Elem. An. C34H62N8NiS2O2: C, 55.35 %; H, 8.47 %; N,15.19 %; S, 8.69 % Found: C, 
54.98 %; H, 8.36 %; N, 15.28 %; S, 8.50 %. 
 
[Cu(CitrGlu)2] 
 
To a solution of ligand CitrGlu (0.40 g, 1.02 mmol) in EtOH (50 mL), at room 
temperature with stirring, was added Cu(OAc)2·H2O (0.1 g, 0.51 mmol). After 3 h the 
solution was poured into a crystallizer and the product was obtained as brown powder 
after slow evaporation of the solvent. 
Cu(CitrGlu)2 was obtained as amorphous solid. 
Yield: 90% 
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Elem. An: C34H60CuN6O10S2 C=48,59%; H=7,18%; N=10,00%  Found C=47,96%; 
H=7,12%; N=10.10%. 
Esi-Ms : m/z 840,55 [ML2+H]
 + 
 
[Ni(CitrGlu)2] 
 
To a solution of ligand CitrGlu (0.30 g, 0.77 mmol) in EtOH (50 mL), at room 
temperature with stirring, was added Ni(OAc)2·4H2O (0.068 g, 0.38 mmol). After 3 h of 
stirring the solution was poured into a crystallizer and the solvent let to slowly 
evaporate. Ni(CitrGlu)2 was obtained as amorphous solid. 
 
Elem. An: C34H60N6NiO10S2  C=37,85%; H=7,21%; N=7,02%  Found C=37,88%; 
H=7,12%; N=7.03%. 
ESI-MS : m/z = 835.32 [ML2+H]
+ 
 
[Cu(VanTSC)2] 
 
To a stirred solution of VanTSC (0.300 g, 1.33 mmol) in EtOH (40mL) was added 
Cu(OAc)2·H2O (0.13 g, 0.66 mmol) and immediately the color turned to green/yellow 
and a precipitate appeared. 
The solution was refluxed for 3 h then was cooled to r.t. and the green precipitate 
collected by filtration. 
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Yield: 62%  
 
Elem. An. C18H20CuN6O4S2  C=42,22%; H=3,94%; N=16,41%  Found C=42,85%; 
H=3,92%; N=16.40%. 
 
[Ni(VanTSC)2] 
 
To a stirred solution of VanTSC (0.350 g, 1.55 mmol) in EtOH (40mL) was added 
Ni(OAc)2·4H2O (0.137 g, 0.77 mmol) and immediately the color turned to. The solution 
was refluxed for 3 h then was cooled to r.t. and green crystals were obtained by slow 
solvent evaporation. 
Yield: 70% 
 
Elem. An. C18H20N6NiO4S2  C=42,22%; H=3,94%; N=16,41%  Found C=42,51%; 
H=3,79%; N=16.53%. 
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Figure 2.8 - ORTEP drawing of  [Ni(VanTSC)2] ( 50% probability plot). 
 
The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using  ORTEPIII. Crystallographic data:  C26H44N6O8S2, Mr = 
691.50,triclinic, space group P-1,  a = 6.859(2) , b = 10.644(4), c= 11.797(4) Å, α 
=72.869(6), β = 78.656(6), γ = 84.751(6)°; V = 806.5(5)Å3, Z = 2, ρcalc = 1.423 Mgm–
3
,  T = 298.15 K, F(000) = 732, crystal size = 0.30x0.30x0.30 mm, index range  =  –8 < 
h < 8, –13 < k < 13, –15 < l < 15, collected reflections = 9823, unique reflections = 
3712, refined parameters = 220, goodness-of-fit = 1.018, final R factor = 0.0605, wR2 = 
0.1736, electronic density residues = 1.19 and –1.15 eÅ–3. 
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[Cu(VanMor)2] 
 
To a stirred solution of VanMor (0.20 g, 0.56 mmol) in EtOH (40mL) was added 
Cu(OAc)2·H2O (0.055 g, 0.28 mmol) and immediately the color turned to brown and a 
precipitate appeared. 
The solution was stirred at r.t. for 3 h then the precipitate was collected by filtration. 
Yield: 64% 
 
Elem. An. C30H42CuN8O4S2  C=49,12%; H=5,77%; N=15,28%  Found C=49,19%; 
H=5,78%; N=15.4%. 
 
[Ni(VanMor)2] 
 
To a stirred solution of VanMor (0.20 g, 0.56 mmol) in EtOH (40mL) was added 
Ni(OAc)2·4H2O (0.05 g, 0.28 mmol) and immediately the color turned to green and a 
precipitate appeared. 
The solution was refluxed for 3 h, then was cooled to r.t. and the precipitate collected by 
filtration. 
Yield: 70% 
 
Elem. An. C30H42N8NiO4S2  C=49,12%; H=5,77%; N=15,28%  Found C=49,21%; 
H=5,77%; N=15.3%. 
ESI-MS : m/z 732,579 [ML2 + H]
+
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[Cu(VanGlu)2] 
 
To a stirred solution of VanGlu (0.30 g, 0.77 mmol) in EtOH (40mL) was added 
Cu(OAc)2·H2O (0.75 g, 0.38 mmol). After 3 h of stirring the solution was poured into a 
crystallizer and was let slowly evaporate. 
Yield: 65% 
 
Elem. An. C30H40CuN6O14S2  C=42,22%; H=3,94%; N=16,41%  Found C=42,51%; 
H=3,79%; N=16.53%. 
ESI-MS : m/z = 835,12267 [ML2 + H]
+
 
 
[Ni(VanGlu)2] 
 
To a stirred solution of VanGlu (0.350 g, 1.55 mmol) in EtOH (40mL) was added 
Ni(OAc)2·4H2O (0.137 g, 0.77 mmol) After 3 h of stirring the solution was poured in a 
crystallizer and was let slowly evaporate and the Ni(VanGlu)2 compound was collected. 
Yield: 70% 
 
Elem. An. C30H40N6NiO14S2  C=37,88%; H=7,20%; N=7,02%  Found C=37,89%; 
H=7,31%; N=7.05%. 
ESI-MS :  m/z = 835,32751 [ML2+H]
+
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[Cu(PyrTSC)Cl2] 
 
To a stirred solution of PyrTSC (0.15 g, 0.62 mmol) in EtOH (40mL) was added 
CuCl2·2H2O (0.106 g, 0.62 mmol) and immediately the color turned to gree 
The solution was refluxed for 3 h then was cooled to r.t. poured into a crystallizer and 
the product obtained for slow solvent evaporation. 
Yield: 46% 
 
Elem. An. C9H16Cl2CuN4O4S, C=26,32%; H=3,93%; N=13,64%  Found C=26,83%; 
H=4.11%; N=13.56%. 
 
[Ni(PyrTSC)Cl2] 
 
To a stirred solution of PyrTSC (0.15 g, 0.62 mmol) in EtOH (40mL) was added 
NiCl2·6H2O (0.14 g, 0.62 mmol) and immediately the color turned to orange and an 
orange precipitate appeared. The solution was refluxed for 3 h then was cooled to r.t. 
and the brown/orange precipitate was collected by filtration. 
Yield: 57% 
 
Elem. An. C9H11Cl2N4NiO2S C=32,42%; H=3,33%; N=16,80%  Found C=39,89%; 
H=4.09%; N=20.68%. 
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[Cu(PyrMor)Cl2] 
 
To a solution of ligand PyrMor (0.10 g, 0.28 mmol) in EtOH (25 mL), at room 
temperature with stirring, was added CuCl2·2H2O (0.048 g, 0.28 mmol). The solution 
turned immediately dark. After 3 h of stirring at r.t. the solution was poured into a 
crystallizer and the solvent slowly evaporated to obtain a green powder. 
Yield: 57%   
 
Elem. An. C15H22Cl2CuN5O3S: C, 39.91%; H, 4.91%; N, 15.51%;. Found:C, 41.1%; H, 
4.8%; N, 16.57%; 
 
[Ni(PyrMor)Cl2] 
 
To a solution of ligand PyrMor (0.20 g, 0.44 mmol) in EtOH (25 mL), at room 
temperature with stirring, solid NiCl2·6H2O (0.10 g, 0.44 mmol) was added. The 
resulting brown solution, was stirred at r.t., and a precipitate appeared. After 2h the 
brown/orange solid was collected by filtration. 
Yield: 61% 
 
Elem. An. C15H22Cl2N5NiO3S: C, 40.34 %; H, 4.97%; N,15.68 %; Found: C, 39.98 %; 
H, 4.6 %; N, 15.28 %; 
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[Cu(PyrGlu)Cl2] 
 
CuCl2·2H2O (0.12 g, 0.74mmol) was added to a solution of PyrGlu (0.300 g, 0.74 
mmol) in MeOH (20 mL). The resulting solution was stirred at r.t. for 4h and a dark 
brown precipitate appeared. The precipitate was collected by filtration.  
Yield 40 % 
 
Elem. An. . C15H22Cl2CuN4O7S C=33,7%; H=3,94%; N=10,44% found C=33,43%; 
H=4,47%; N=10,36%. 
ESI-MS : m/z = 464.03 [ML+H]
 +
 
 
[Ni(PyrGlu)Cl2] 
 
NiCl2·6H2O (0.17 g, 0.74mmol) was added to a solution of PyrGlu (0.300 g, 0.74 mmol) 
in MeOH (20 mL). The resulting solution was stirred at r.t. and an orange precipitate 
appeared. After 4 h the solid was collected by filtration. 
Yield: 44%  
Elem. An. C15H22Cl2N4NiO7S C=33,93%; H=3,97%; N=10,55%. found C=33,84%; 
H=3,93%; N=10,61%.  
ESI-MS: m/z = 491,07388 [ML+H+MeOH]
 +
. 
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Chapter 3 
Theoretical studies, synthesis and biological evaluation of glycosylated 
thiosemicarbazones 
3.1 Ribonucleotide reductase 
As already described in the introduction, ribonucleotide reductase (RNR, also known as 
ribonucleotide diphosphate reductase) is one of the putative targets of 
thiosemicarbazones. During my doctoral period, in collaboration with prof. E. Polverini 
of the Department of Physics in our University, a study aimed at evaluating the possible 
interactions of thiosemicarbazones with ribonucleotide reductase was carried out giving 
us a hint in the formulation of new thiosemicarbazones. 
Ribonucleotide reductase is an enzyme which catalyzes the conversion of 
ribonucleotides (NTPs) to their corresponding deoxyribonucleotides (dNTPs), which are 
the building blocks for DNA replication and repair in all living cells
1
. In this way this 
enzyme catalyzes the rate limiting step in DNA synthesis in the cell cycle
2
. The activity 
of this enzyme is under strict control and this highlights the importance of a balanced 
supply of dNTPs for error-free DNA synthesis. Unbalanced dNTP pools lead to 
misincorporation of nucleotides into DNA, mutations and cell death
3
. Eukaryotic 
enzymes consist of two homodimeric proteins, R1 (α2) and R2 (β2) (Fig. 3.1). 
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Figure 3.1 – Ribonucleotide reductase 
 
The R1 (α2) subunit harbors two allosteric sites, the catalytic site and redox active 
disulfide
4
 while the R2 (β2) subunit contains an oxygen-linked diferric center and a 
stable tyrosyl radical
1
. Depending on the allosteric configuration, one of the four 
ribonucleotides binds to the catalytic site 
1
.  
 
3.1.1 Allosteric regulation 
Allosteric regulation of RNR is a mechanism which allows the enzyme maintain 
balanced the pool of the four deoxynucleotides and to adapt rapidly to changes in the 
requirements for dNTPs
5
. Effectors bind to two separate sites (Fig. 3.1): the “activity 
site” which regulate the general activity of RNRs and the “specificity site” which 
regulate the substrate specificity. Nucleoside triphosphates are effectors, whereas 
nucleoside diphosphates are its substrates. The effectors induce conformational changes 
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of the protein structure providing the signal for the required adaptation at the catalytic 
site
1,6
. 
 
3.1.2 Docking 
In the field of molecular modeling, docking is a method which predicts the 
preferred orientation of one molecule to a second when bound to each other to form a 
stable complex. Different couples effector-substrate modulate conformation of loop 2 
(red in Fig. 3.2), for example dADP determine specificity for CDP substrate (see Fig. 
3.2a). Once inside site S dATP, possessing an adenine which is a bicyclic system, 
occupies a bigger volume than the corresponding pyrimidine derivative, inducing a 
folding of loop 2 towards site C. As a consequence space inside site C become reduced 
and is favoured only the passage of pyrimidinic nucleotide as CDP.  
 
 
 
Figure 3.2 
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Opposite behaviour has the dTTP-GDP couple, because the effector possesses a 
pyrimidinic ring and this shifts loop 2 to site S, letting site C more accessible to an 
adenosinic nucleotide like GDP (see Fig. 3.2b).  
For the reasons mentioned above and because during the docking simulation receptor 
stays rigid, two different structure were chosen, which possess different conformations 
of loop 2 and sites S and C. Docking simulation has been used to check the affinity of 
our exogenous ligands for these sites, their disposition inside them and if the binding 
energy is comparable with the energy of endogen ligands. 
For the docking experiments two different ribonucleotide reductase structures were 
taken from the PDB (Protein data bank) database. For all these structures the protein 
source is Homo sapiens (RNR of class I). 
The structure chosen are 2WGH and 3HND. 2WGH has site C occupied by CDP and 
site S by dATP while 3HND has site C occupied by GDP and site S by dTTP (Tab. 3.1). 
 
 
 
 
 
Table 3.1 
 
The results of docking are clusters of conformations with a RMSD (root mean square 
deviation) below a threshold of 2 Å. RMSD is a measure of the average distance among 
atoms corresponding of overlapped structures; the lower is this value the more similar 
are structures. The larger a cluster is the higher probability the conformation with lowest 
 Site C Site S 
2WGH CDP dATP 
3HND GDP dTTP 
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energy is favoured. In these docking experiments exogenous molecules evaluated are 
glycosylated thiosemicarbazones. 
Looking at 2WGH table it is possible to note that exogenous molecules cannot compete 
with the specificity site but using as a model the acetylated glucose derivatives things 
change dramatically as can be seen from Tab. 3.2.  
 
2WGH  3HND 
Molecule Site S 
(Kcal/mol) 
Site C 
(Kcal/mol) 
Molecule Site S 
(Kcal/mol) 
Site C 
(Kcal/mol) 
CDP -9.23 - 6.44 GDP -10.23 -7.69 
dATP -11.75 - dTTP -13.4 -8.05 
CitrGlu -6.76 -6.53 CitrGlu - -5.8 
PyrGlu -6.47 -3.64 PyrGlu -5.0 -4.81 
VanGlu - -6.66 VanGlu -4.95 -5.36 
 
Table 3.2 – Binding energies for glucosylated thiosemicarbazones 
 
As can be noticed the binding energies in the catalytic site for the acetylated glucose 
derivatives (gray background in Tab. 3.3) are of the same order of magnitude as the 
natural molecules and this has encouraged me in the synthesis of glycosylated 
thiosemicarbazones. 
 
 
 
71 
 
2WGH  3HND 
Molecule Site S 
(Kcal/mol) 
Site C 
(Kcal/mol) 
Molecule Site S 
(Kcal/mol) 
Site C 
(Kcal/mol) 
CDP -9.23 - 6.44 GDP -10.23 -7.69 
dATP -11.75 - dTTP -13.4 -8.05 
CitrAcGlu -6.02 -7.91 CitrAcGlu -4.83 -7.35 
PyrAcGlu - -6.66 PyrAcGlu -4.7 -6.92 
VanAcGlu - -6.59 VanAcGlu -5.55 -7.23 
 
Table 3.3 – Binding energies for acetylated glucosyl thiosemicarbazones 
 
3.2 Synthesis of glycosylated thiosemicarbazones 
Considering the interesting data obtained we decided to synthesize new glycosylated 
thiosemicarbazones employing not only glucose but galactose as well. The idea was to 
prepare tridentate ligands bearing the sugar moiety at N1 keeping free the N4 (Fig. 3.3) 
 
. 
 
Figure 3.3 – Glucosyl (left) and galactosyl (right) thiosemicarbazones (GluOAcTriTSC 
and GalOAcTriTSC) 
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Figure 3.4 – Synthesis of GluOAcTriTSC and GalOAcTriTSC 
 
The general synthesis of GluOAcTriTSC and GalOAcTriTSC (Fig. 3.4) was performed 
by brominating acetylated sugars (4- dimethylaminopyridine, Py, Ac2O). Halogenated 
sugars were sonicated
7
 for 10’ in presence of sodium azide to obtain a β-azo-sugar 
which subsequently underwent to Azide-Alkyne Huisgen Cycloaddition to give a 
hydroxy-glycosyl-triazole. To form a thiosemicarbazone the hydroxyl group was 
oxidized to aldehyde in presence of oxalyl chloride and dimethyl sulfoxide (Swern 
oxidation) at -80°C to avoid the occurring of side reactions. Once obtained, the 
aldehyde was condensed with the thiosemicarbazide to form the desired 
thiosemicarbazones. 
As the complexes of glycosylated citronellal were the most active among the 
glycosylated series (Chapter 2) we decided to prepare and test the copper(II) and 
nickel(II) derivatives of acetylated CitrGlu. Ligand synthesis is reported in the 
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experimental section of chapter 2. The synthesis of both complexes was carried out in 
ethanol using a molar ratio metal-ligands 1:2, but the only compounds we were able to 
characterize was the nickel complex while all attempts to obtain the copper complex did 
not give to desired product. 
 
3.3 Biological assays 
Preliminary biological tests were done on Ni(CitrGluOAc)2 and GalTriazTSC 
derivatives but U937 cells did not show any appreciable response even at concentrations 
of 100 and 50 μM respectively. 
 
3.4 Conclusions 
Interactions between a series of glycosylated thiosemicarbazones previously synthesized 
and two different structures of ribonucleotide reductase found in the Protein Data Bank 
were evaluated by docking studies. These studies revealed that these compounds have 
no affinity for the specificity site S  and low affinity for the catalytic site C. Observing 
that the few interactions of the glucosyl moiety with the environment of the catalytic 
site C were due to its small size we attempted further docking studies using as a model 
the acetylated glucosyl derivatives. These molecules, presenting a larger steric 
hindrance and higher number of hydrogen acceptor atoms, gave promising results as 
potential inhibitors. In fact the binding energies of acetylated glucose derivatives are 
comparable with the energy associated to the natural ligands (CDP and GDP). 
Encouraged by these results two new glycosylated ligands were synthesized: a glucose 
and a galactose derivative.  
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As stated above, since the complexes of glycosylated citronellal were the most 
promising, we focused our experiments on the copper(II) and nickel(II) derivatives of 
the acetylated CitrGlu. The only compound we were able to fully characterize was the 
nickel complex while the expected copper complex was not obtained. 
Biological assays were performed on three of the above mentioned compounds: the 
GalTriazTSC, the CitrAcGlu and its nickel complex Ni(CitrAcGlu)2 but we could not 
observe any activity even at high concentrations. 
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3.5 Experimental 
TLC were performed on Silica gel Merck 60 F254 aluminium sheets. Flash 
chromatography was performed on MP Silica 63-200 mesh 60Å (EchoChrom™), 1H 
and NMR spectra were recorded on Bruker 300 Avance and Bruker 400 Avance 
spectrometers, at 300 K. The reported J values are referred to H,H coupling constants. 
Chemical shifts are reported as δ values in ppm using the solvent residual peak as 
internal standard. Elemental analysis were recorded on Flash 1112 Series Analyser (CE 
Instruments) Mass spectra by electrospray ionization (ESI) methods were recorded on 
LTQ ORBITRAP XL Thermo. 
 
3.5.1 Ligands synthesis 
[AzGluOAc] 
1-Azido-1-deoxy-β-glucopyranoside tetraacetate 
 
 
 
A solution of aceto bromo-α-D-glucose (3 g, 7.29 mmol) and sodium azide (0.57 g, 8.76 
mmol) in DMSO (35 mL) was sonicated for 10’. After that time the solution was diluted 
with water (100 mL) and extracted twice with chloroform (100 mL). The organic phase 
was anhydrified with Na2SO4 
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Anhydrous and concentrated under pressure to give a white solid which crystallize. I f 
necessary the product was purified by flash chromatography (AcOEt/C6H12 1:2). 
Yield: 95% 
 
1
H NMR (300 MHz, CDCl3) : δH (ppm) 5.24 (t, J = 9.43 Hz, 1H). 5.13 (t, J = 9.67 Hz, 
1H), 4.98 (t, J  = 8.94 Hz, 1H), 4.67 (d, J = 8.84 Hz, 1H), 4.30 (dd, J = 12.48, 4.76 Hz, 
1H), 4.19 (dd, J = 12.45, 2.33 Hz, 1H), 3.82 (ddd, J = 9.91, 4.73, 2.35 Hz, 1H), 2.10 
(m, 12H, OAc), 
 
[GluOAcTriOH] 
4-Hydroxymethyl-1-(2’,3’,4’6’-tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazole 
 
 
 
To a solution of glycosyl azide (1.1 g, 2.41 mmol)  and propargyl alcohol (0.189 mL, 
3.2 mmol) in acetone (10 mL) were added a solution of   CuSO4∙5H2O (0.124 g, 0.5 
mmol) in water (5 mL) and ascorbic acid (0.88 g, 0.5 mmol) in water (5 mL). The 
solution was sonicated for 1h. After that time solvent was let slowly evaporate to obtain 
white crystals. 
Yield: 65% 
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1
H NMR (300 MHz, CDCl3) : δH (ppm) 7.85 (s, 1H, NCH=C), 5.92 (d, J = 9.10, 1H, H-
1), 5.46 (m, 1H, H-2, H-4), 5.27 (t, J = 9.10 Hz, 1H, H-3), 4.80 (s, 2H, CH2OH), 4.30 
(dd, J = 12.60, 4.90 Hz, 1H, H-6), 4.16 (dd, J = 12.60, 2.06 Hz, 1H, H-6), 4.04 (ddd, J 
= 10.08, 4.90, 2.06 Hz, 1H, H-5), 2.90 (s, 1H, CH2OH), 2.08 (s, 6H, OAc), 2.04 (s, 3H, 
OAc), 1.88 (s, 3H, OAc) 
 
 
 
Figure 3.5. ORTEP drawing of 4-Hydroxymethyl-1-(2’,3’,4’6’-tetra-O-acetyl-β-D-
glucopyranosyl)-1,2,3-triazole ( 50% probability plot). 
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The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-K (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using  ORTEPIII. Crystallographic data:  C17H23N3O10, Mr = 427.37, 
orthorhombic, space group P212121,   a = 8.134(1) , b = 15.190(2), c= 17.002 (3) Å; V = 
2100.7(5)Å
3
, Z = 4, ρcalc = 1.335 Mgm
–3
,  T = 298.15 K, F(000) = 896, crystal size = 
0.60x0.60x0.60 mm, index range  =  -11 < h < 11, -21 < k < 21, -24 < l < 24, collected 
reflections = 34084, unique reflections = 6423, refined parameters = 311, goodness-of-
fit = 1.062, final R factor = 0.0517, wR2 = 0.1597, electronic density residues = 0.26 
and –0.22 eÅ–3. 
 
[GluOAcTriO] 
4-Formyl-1-(2’,3’,4’6’-tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazole 
 
 
 
A stirred solution of oxalyl chloride (0.117 mL, 1.29 mmol) in dichloromethane (7 mL) 
was cooled to -78°C, after that a solution of dimethylsulfoxide (0.117 mL, 1.29 mmol) 
in dichloromethane (7 mL) was rapidly added and the temperature kept at -78°C. After 
5’ minutes was slowly (10’) dropped a solution of glycosyl triazole (0.2 g, 0.46 mmol) 
in dichloromethane keeping the temperature constant (-78°C). The solution was stirred 
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for 15’ and after that period of time triethylamine (4 mL, 30mmol) was added. Stirring 
was continued for 5’ at -78°C and then temperature was let rise r.t. The solution was 
filtered,  washed with water, the organic phase was then anhydrificated with Na2SO4 
anhydrous and finally concentrated under reduced pressure. 
The product was purified by flash chromatography (AcOEt/C6H12 1:2). 
Yield: 80% 
 
1
H NMR (300 MHz, CDCl3) : δH ppm 10.18 (s, 1H, CHO), 5.95 (d, J = 10.06 Hz, 1H, 
H-1), 5.48 – 5.41 (m, 2H), 5.28 (t, J =10.06, 1H), 4.34 (dd, J = 12.40, 4.85 Hz, 1H, H-
6), , 4.20 (dd, J = 12.40, 2.30 Hz, 1H, H-6), 4.06 (ddd, J = 10.06, 4.85, 2.30 Hz, 1H, H-
5), 2.12 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.06 (s, 3H, OAc), 1.94 (s, 3H, OAc) 
 
[GluOAcTriTSC] 
1-(2’,3’,4’6’-tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazo-4-Thiosemicarbazone 
 
 
 
After dessolution of (0.820 g, 1.9 mmoli) in ethanol (30 mL) thiosemicarbazide (0.190 
g, 2.09 mmol) was added and the mixture was stirred at r.t. for 24 h resulting in a white 
precipitate which was filtered and washed with ethanol.  
Yield : 94%  
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1
H NMR (300 MHz, DMSO-d6) : δH ppm 10.38 (s, 1H, NH), 8.83 (s, 1H, CH=N), 7.91 
(s, 1H, CH=C), 6.49 (s, 2H, NH2),  6.40 (d, J = 9.20 Hz, 1H, H-1), 5.61 (t, J = 9.20 Hz, 
1H, H-3), 5.51 (t, J = 9.20 Hz, 1H, H-2), 5.14 (t, J = 9.20 Hz, 1H, H-4), 4.40 (ddd, J = 
9.20, 5.47, 2.33 Hz ,1H, H-5), 4.18 (dd, J = 12.31, 5.47 Hz, 1H, H-6), 4.08 (dd, J = 
12.31, 2.33 Hz, 1H, H-6), 2.05 – 1.83 (4s, 12H, OAc)  
 
[GalOAc] 
Galactose pentaacetate 
 
 
 
To a round flask containing D-Galactose (1g, 9.24 mmol) in AcO2 (7 mL) were added 
pyridine (7mL) and a small amount of 4- dimethylaminopyridine. The solution was 
stirred in an ice-cold bath for 5h and than at r.t. for 18h.  Dichlorometane (20mL) and 
water (20mL) were added to the solution, the organic phase was then separated and 
consecutively washed with a sat. aq. CuSO4 until the dark blue color disappear, water 
(20mL), dried over Na2SO4 and concentrated under reduced pressure to give an oil 
which crystallize. 
Yield: 92% 
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1
H NMR (300 MHz, CDCl3) : δH (ppm)  5.71 (d, 1H, H-1), 5.43 (m, 1H, H-4), 5.33 (t, 
1H, H-2), 5.09 (dd, 1H, H-3), 4.16 (m, 1H, H-6), 4.17 (m, 1H, H-7), 4.07 (m,1H, H-5), 
2.17 – 2.00 (4s, 15H, 5 OAc) 
 
[GalOAcBr] 
Acetobromo-α-D-galactose 
 
 
 
In un pallone a due colli contenente galactosio pentacetato (1 g, 2.56 mmol) in 
diclorometano (5 ml),  mantenuto sotto atmosfera di azoto, è stato aggiunto HBr 33% 
(1.2 mL, 7.68 mmol). La soluzione risultante è stata agitata fino a quando la TLC 
(AcOEt/C6H12 2:3) non ha mostrato la scomparsa del composto di partenza. 
Successivamente la soluzione è stata concentrata sotto pressione, sciolta in 
diclorometano (10 mL), lavata ripetutamente con NaHCO3 aq. sat., acqua e infine la fase 
organica è stata anidrificata e concentrata sotto pressione per dare un olio che all’aria 
cristallizza. Se necessario il solido ottenuto è stato purificato tramite flash cromatografia 
con miscela (AcOEt / C6H12 2:3) 
Yield: 87% 
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1
H NMR (300 MHz, CDCl3) : δH (ppm) 6.69 (d, J = 3.92 Hz, 1H, H-1), 5.51 (d, J = 
3.12 Hz, 1H, H-4), 5.39 (dd, J = 10.67, 3.12 Hz, 1H, H-3), 5.04 (dd, J = 10.67, 3.92 Hz, 
1H, H-2), 4.48 (t, J = 6.54 Hz, 1H, H-5), 4.18 (dd, J = 11.40, 6.54 Hz, 1H, H-6), 4.10 
(dd, J = 11.40, 6.54 Hz, 1H, H-6), 2.07 (4s, 12H, OAc) 
 
[AzGalOAc] 
1-Azido-1-deoxy-β-galactopyranosyl tetra acetate 
 
 
 
A solution of aceto bromo-α-D-galactose (3 g, 7.29 mmol) and sodium azide (0.57 g, 
8.76 mmol) in DMSO (35 mL) was sonicated for 10’. After that time the solution was 
diluted with water (100 mL) and extracted twice with chloroform (100 mL). The 
organic phase was anhydrificated with Na2SO4. 
Anhydrous and concentrated under pressure to give a white solid which crystallize. I f 
necessary the product was purified by flash chromatography (AcOEt/C6H12 1:2). 
Yield : 93% 
 
1
H NMR (300 MHz, CDCl3) : δH (ppm) 5.45 (dd, J = 3.29, 1.09 Hz, 1H, H-4), 5.19 (dd, 
J = 10.39, 8.68 Hz, 1H, H-2), 5.06 (dd, J = 10.36, 3.34 Hz, 1H, H-3), 4.62 (d, J = 8.67 
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Hz, 1H, H-1), 4.20 (dd, J = 6.54, 2.39 Hz, 2H, H-6), 4.04 (m, 1H, H-5), 2.09 (4 s, 12H, 
OAc). 
 
[GalOAcTriOH] 
4-Hydroxymethyl-1-(2’,3’,4’6’-tetra-O-acetyl-β-D-galactopyranosyl)-1,2,3-triazole 
 
 
 
To a solution of 1-Azido-1-deoxy-β-galactopyranosyl tetra acetate (0.90 g, 2.41 mmol) 
and propargyl alcohol (0.170 mL, 2.9 mmol) in t-Butanol (10 mL) were added two 
acqueous solutions (5 mL) of CuSO4∙5H2O (0.134 g, 0.54 mmol) and ascorbic acid 
(0.188 g, 1.07 mmol). The resulting solution was reflue under nitrose atmosphere and 
monitored by TLC (AcOEt/C6H12 2:1). After 4 h water was added (100 mL) and the 
organic phase was extracted twice with ethyl acetate (100mL. The organic phase was 
anhydrificated with Na2SO4 anhydrous and concentrated under reduced pressure. 
Finally the product was purified by flash cromatografia (AcOEt/C6H12 1:2). 
Yield: 77,2% 
 
1
H NMR (300 MHz, CDCl3) : δH (ppm)  7.89 (bs, 1H, NCH=C), 5.87 (d, J = 9.36 Hz, 
1H, H-1), 5.57 (m, 2H, H-2, H-4), 5.27 (dd, J = 10.25, 3.37 Hz, 1H, H-3), 4.84 (s, 2H, 
CH2OH), 4.22 (m, 3H, H-5, H-6, H-6’), 2.25-2.03 (4s, 12H, OAc) 
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[GalOAcTriO] 
4-Formyl-1-(2’,3’,4’6’-tetra-O-acetyl-β-D-galactopyranosyl)-1,2,3-triazole 
 
 
 
A stirred solution of oxalyl chloride (0.117 mL, 1.29 mmol) in dichloromethane (7 mL) 
was cooled to -78°C, after that a solution of dimethylsulfoxide (0.117 mL, 1.29 mmol) 
in dichloromethane (7 mL) was rapidly added and the temperature kept at -78°C. After 
5’ minutes was slowly (10’) dropped a solution of galctosyl triazole (0.2 g, 0.46 mmol) 
in dichloromethane keeping the temperature constant (-78°C). The solution was stirred 
for 15’ and after that period of time triethylamine (4 mL, 30mmol) was added. Stirring 
was continued for 5’ at -78°C and then temperature was let rise r.t. The solution was 
filtered,  washed with water, the organic phase was then anhydrificated with Na2SO4 
anhydrous and finally concentrated under reduced pressure. 
The product was purified by flash chromatography (AcOEt/C6H12 1:2). 
Yield: 74% 
 
1
H NMR (300 MHz, CDCl3) : δH (ppm) 10.17 (s, 1H, CHO), 8.44 (s, 1H, NCH=C), 
5.94 (d, J = 9.15 Hz, 1H, H-1), 5.59 (d, J = 3.30 Hz, 1H, H-4), 5.52 (t, J = 9.15, 1H, H-
2), 5.31 (dd, J = 9.15, 3.30 Hz, 1H, H-3), 4.21 (m, 3H, H-5, H-6, H-6’), 2.24 (s, 3H, 
OAc) 2.06 (s, 3H, OAc), 2.03 (s, 3H, OAc), 1.93 (s, 3H, OAc) 
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Figure 3.5. ORTEP drawing of 4-formyl-1-(2’,3’,4’6’-tetra-O-acetyl-β-D-
galactopyranosyl)-1,2,3-triazole ( 50% probability plot). 
 
The X-ray structure was solved from data collected on a Siemens AED diffractometer. 
Cu-K (λ = 1.54178 Å) The structure was solved by direct methods and refined using 
SHELXL97. The drawing was plotted using  ORTEPIII. Crystallographic data:  
C17H23N3O10, Mr = 427.37, orthorhombic, space group P212121,   a = 9.0621(5) , b = 
25.398(5), c= 9.0492(9) Å; V = 2082.8(5)Å
3
, Z = 4, ρcalc = 1.363 Mgm
–3
,  T = 298.15 K, 
F(000) = 896, crystal size = 0.60x0.30x0.30 mm, index range  =  0 < h < 11, 0 < k < 30, 
0 < l < 11, collected reflections = 2289, unique reflections = 2258, refined parameters = 
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271, goodness-of-fit = 0.928, final R factor = 0.0456, wR2 = 0.1313, electronic density 
residues = 0.18 and –0.14 eÅ–3. 
 
[GalOAcTriTSC] 
4-Tiosemicarbazone-1-(2’,3’,4’6’-tetra-O-acetyl-β-D-galactopyranosyl)-1,2,3-
triazole 
 
 
 
After dessolution of formyl galacto triazole (0.820 g, 1.9 mmoli) in ethanol (30 mL) 
thiosemicarbazide (0.190 g, 2.09 mmol) was added and the mixture was stirred at r.t. for 
24 h resulting in a precipitate which was filtered and washed with ethanol.  
Yield: 94% 
 
1
H NMR (300 MHz, DMSO-d6) : δH (ppm) 11.54 (s, 1H, NH), 8.88 (s, 1H, HC=N), 
8.12 (s, 1H, HCNN), 8.08 (s, 1H), 6.35 (d, J = 8.78 Hz, 1H, H-1), 5.49 (m, 3H, H-2, H-
3, H-4), 4.70 (m, 1H, H-5), 4.16 (dd, J = 11.42, 4.91 Hz, 1H, H-6), 4.05 (dd, J = 11.66, 
7.27 Hz, 1H, H-6’), 2,1 – 1.8 (4s, 3H, OAc) 
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Complex synthesis 
[Ni(CitrGluOAc)2] 
 
A solution of Ni(OAc)2·4H2O (0.33 g, 0.13 mmol) and CitrGluOAc (0.15 g, 0.26 mmol) 
in EtOH (35 mL) was refluxed for 4 h, then cooled to r.t. The solution was poured into a 
crystallizer and the solvent slowly evaporate to afford a dark green-brown solid. 
Yield: 90% 
 
Elem. An: C50H76N6NiO18S2  C=51,24%; H=6,54%; N=7,17%  Found C=51,28%; 
H=6,62%; N=7.03%. 
ESI-MS : m/z = 1172.1  [ML2+H]
+
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Chapter 4 
Thiosemicarbazones as inhibitors of topoisomerase IIα 
4.1 Topoisomerase IIα 
Topoisomerase are a family of ubiquitous enzymes involved in regulation of 
supercoiling DNA
1
. Type II topoisomerases are cellular enzymes involved in altering 
the supercoiled DNA, in segregation of newly replicated chromosome pairs and in 
chromosome condensation
2,3
. The eukaryotic enzymes are dimers (170 k-Da) while 
prokaryotic are A2B2 tetramers.  
Type II topoisomerases work by cleaving and opening one DNA duplex, passing 
a second duplex through the opening and then resealing the break
4,5
. The DNA cleavage 
is a transesterification, mediated by magnesium, between a pair of tyrosyl residues and a 
pair of a DNA phosphodiester base
3
. 
 
Figure 4.1 - Topoisomerase II model of catalytic reaction 
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In Fig. 4.1 is depicted the catalytic reaction cycle of topoisomerase II: the ATPase 
domain, B’ and A’ subfragments are coloured yellow, red and blue, respectively. The 
G-segment DNA (containing DNA gate) is grey and the transported T-segment is green. 
The catalytic cycle begins with the binding of DNA substrate by Topo-II (1). Once 
bound ATP (represented by asterisks) (2) and the T-segment a series of conformational 
changes occur causing the split of the G-segment by the A’ subfragments. 
Concomitantly, the ATPase domains dimerize and the T-segment is transported through 
the break and into the central hole (4). Once the DNA is transported, the G-segments is 
resealed and the T-segment released from the enzyme through the opening of the dimer 
interface between A’(5). The interface between the two A’ subfragments again 
dimerizes and ATP is hydrolized and released to regenerate the starting state (2)
3
. 
 
4.1.1 Topoisomerase inhibition 
Since the discovery that Topoisomerase II (Topo-II) was the target of active cancer 
drugs, in particular doxorubicin and etoposide, this enzyme has gained some attention. 
(Fig. 4.2)
6,7
. 
 
 
Figure 4.2 – Doxorubicin (left), etoposide (right) 
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Studies revealed that the most clinically active drugs that target Topo-II generate 
enzyme-mediated DNA damage
7,8
. Drugs targeting Topo-II are classified in two groups, 
according to their effect on enzyme function (Fig. 4.3). The first group, which includes 
doxorubicin and etoposide is called Topo-II poisons. The mechanism of action of this 
class of drugs is to stabilize the cleavable complex forming a drug-enzyme-DNA 
complex which is toxic and can induce apoptosis. Drugs belonging to the second class, 
called catalytic inhibitors, interfere with Topo-II catalytic activity, preventing DNA-
enzyme linkage or its release from DNA, leading to cell death
9
. Inhibition of Topo-II at 
several different points of the enzyme catalytic cycle entails different cellular and 
biochemical consequences. 
 
 
 
Figure 4.3 – Mode of action of different Topo-II inhibitors 
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Antibiotics belonging to the family of cumarines like novobiocin and coumermycin, 
known to inhibit nucleic acid synthesis in bacteria, compete with ATP for binding 
Topo-II
10
. Others drugs used in cancer therapy, which can inhibit Topo-II are 
aclarubicin, merbaron, etoposide. Aclarubicin, an anthracyclin drug, used for the 
treatment of acute myelocytic leukemia, inhibits the binding of DNA to Topo-II, acting 
as intercalating agent
11
. 
Another way to block the catalytic activity is to prevent the relegation of the cleaved 
DNA. This is the mechanism of action of etoposide, which stabilizes each of the two 
scissile bonds of the cleavage complex inducing in this manner cell death
12
. 
Topo-IIα can also be inhibited after that the strand passage is completed but before ATP 
hydrolysis by bisdioxopiperazines, such as dexrazoxane (ICRF-187), which inhibits 
ATP hydrolysis and maintains the enzyme close around the DNA
11
. 
 
4.2 Thiosemicarbazones and topoisomerase IIα 
Several research groups have investigated thiosemicarbazones as antitumor agents and 
have shown that some of these compounds inhibit Topo-II, stabilizing the cleavable 
products formed by Topo-II and DNA
13-15
. A few papers have also been published 
regarding thiosemicarbazones
16,17
 and as metal complexes
18,19
. Ashutosh Rao et al.
16
 
showed that Dp44mT (Fig. 4.4), a molecule with antitumor activity used in mice 
xenografted with a range of human tumors, causes DNA damage and inhibition of 
Topo-IIα activity. In their work they demonstrated that Dp44mT can selectively inhibit 
Topo-IIα and not Topo-I nor Topo-IIβ. 
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Figure 4.4 – Dp44mT a potent iron chelator 
 
The Topo-IIα-mediated activity of Dp44mT was observed using Nalm-6 leukemia cells 
that were heterozygous deficient for Topo-IIα, in which Dp44mT had only half of the 
cytotoxic activity compared with wild-type cells. In addition, Dp44mT is able to induce 
the formation of stable cellular Topo-IIα-DNA complexes, indicative of Topo-IIα 
poisoning in cancer cells. In the same period Huang et al.
17
 discovered that, among a 
new series of α-heterocyclic TSCs, one compound (4,4’N-Dimethyl quinoline 
thiosemicarbazone, TSC24) (Fig 4.5) exhibited broad antiproliferative activity in a 
panel of human tumor cells and suppressed tumor growth in mice. 
 
 
 
Figure 4.5 – 4,4’N-Dimethyl quinoline thiosemicarbazone (TSC24) 
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Mechanism studies revealed that TSC24 acts as a topoisomerase II-α catalytic inhibitor. 
First, HL-60/MX2 cells, which are resistant to Topo-II poison such as etoposide 
phosphate (VP-16) were fully sensitive to TSC24. Second, TSC24 failed to trap Topo-
IIΑ-DNA complexes but antagonized etoposide-stabilized cleavage complexes in the 
presence of ATP. Finally, TSC24 was unable to induce DNA damage but countered 
etoposide-mediated DNA damage in HT-29 cells. Further studies revealed that TSC24 
inhibited Topo-II-mediated ATP hydrolysis. High affinity of TSC24 for HsATPase was 
revealed with SPR assay (surface plasma resonance spectroscopy). Molecular docking 
predicted that TSC24 act as an ATP competitor, binding to ATP-binding pocket in a 
planar conformation with the heterocyclic nitrogen, imine nitrogen, and sulfur forming a 
meridional tridentate coordination environment
17,18
. 
Recent discovery of the topoisomerase IIα (Topo-IIα) inhibition property of 
thiosemicarbazones and their metal complexes expanded the array of biochemical 
targets and reinforced the potential application of metal thiosemicarbazonato complexes 
in cancer research. Furthermore recent publications showed in vivo and in vitro 
inhibition of Topo-IIα by α-heterocyclic thiosemicarbazones and their Cu(II) complexes 
at IC50 below that of the widely employed Topo-IIα poison etoposide (VP-16). The 
importance of Topo-IIα in many forms of cancer and the great potential of 
thiosemicarbazones and their metal complexes as chemotherapeutics agents open new 
pathways of study
18
. 
 
In 2006 Lihui Wei et al
19
 investigated the relationship between the in vitro and in vivo 
behavior of novel 
64
Cu-TSC complexes (Fig. 4.6) and the expression of Topo-II 
activity. Small-animal PET of animals with L1210 tumors (high Topo-II expressing 
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cells) showed excellent tumor accumulation compared with that of animals with PC-3 
tumors (low Topo-II expressing) and the L1210 tumor uptake was significantly reduced 
by coadministration of a Topo-II poison. 
 
 
 
Figure 4.6 - Structures of ligands EPH142, EPH143, EPH144, 
and EPH270 used to prepare 
64
Cu labeled complexes 
 
Similar results appeared in a recent work
18
 where several copper (II) complexes of α-
heterocyclic thiosemicarbazones of formyl pyridine and acetyl pyrazine (Fig. 4.7) were 
tested in vitro as Topo-IIα inhibitors and as antiproliferative in SK-BR-3 and MCF-7 
breast cancer cells, expressing respectively high and low levels of Topo-IIα. 
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Figure 4.7 – Biological activity of α-heterocyclic thiosemicarbazones and their Cu(II) 
complexes. 
 
Cu(TSC)Cl complexes resulted to inhibit Topo-II more strongly than the ligands alone 
and possess with respect to them a GI50 in most cases lower by well over an order of 
magnitude. Gel electrophoresis experiments revealed that Cu(TSC)Cl complexes are 
catalytic inhibitors rather than poisons, even though the mechanism remains unknown. 
Considering copper complexes, noteworthy are their low GI50 values from <1 to 6 µM 
with SK-BR-3 cells and from 2 to 12 µM with MCF-7 cells suggesting that Topo-IIα 
inhibitions may play a role in antiproliferative effects of these complexes.  
 
4.3  Project description 
Taking into account the hypothesized action mechanism of these α-heterocyclic 
compounds, in particular TSCS24
17
, and the higher activity they show when bound to 
metals, I decided to synthesize tridentate derivatives using as starting aldehydes formyl 
quinoline and two substituted isatins (5-fluoro and sodium 5-sulfonate isatins - Fig. 4.8) 
to study how the presence of substituents on the thiosemicarbazide fragment and how 
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the coordination to copper(II) and nickel(II) can influence the biological activity of a 
this group of thiosemicarbazones. and also how the presence of a charge on the 5-
sulfonate isatin can affect the internalization mechanism. 
 
 
 
Figure 4.8 – 5-fluoro and sodium 5-sulfonate isatins 
 
Isatin was chosen for two reasons: the first is that its thiosemicarbazonates are known to 
possess biological activity
20
 and the second is that once condensed with a 
thiosemicarbazide, the resulting thiosemicarbazone behaves as a tridentate ligand 
through the oxygen of the carbonyl group in β to the pyrrolidine nitrogen. Differently 
from my previous studies, besides checking the proliferation inhibition activity, I have 
also tried a different approach in an attempt to shed some light on the action 
mechanisms of these molecules by focusing my attention on the direct effect of 
thiosemicarbazones on one of the putative target enzymes: topoisomerase IIα.  
 
4.3.1  Ligands and complexes 
The thiosemicarbazone ligands were synthesized via the typical condensation route 
from their parent thiosemicarbazides and the appropriate ketone or aldehyde. N2 and N4 
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substituents were altered to provide a structurally systematic series of compounds. In 
the following tables (Tab. 4.1 and Tab. 4.2) is the list of the synthesized compounds. 
 
 
 
 
 
 
 
Table 4.1 – Quinoline derivatives 
 
 
 
 
 
Table 4.2 – Isatin derivatives 
 R1 R2 R3 
QN42M H Me Me 
QN41M H H Me 
QN41E H H Et 
QN41Al H H Allyl 
QN41Ph H H Phenyl 
QN21M Me H H 
QN42H H H H 
 R1 R2 R3 
FIN42M F Me Me 
FIN41M F H Me 
FIN41E F H Et 
FIN41Ph F H Phenyl 
SIN42M SO3Na Me Me 
SIN41M SO3Na H Me 
SIN41E SO3Na H Et 
SIN41Ph SO3Na H Phenyl 
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Subsequently, the copper and nickel complexes were prepared by heating a solution of 
the ligands with CuCl2 and NiCl2 respectively. 
 
4.4 Proliferation inhibition assay 
Due to the costs of the biological assays only part of the synthesized compounds were 
tested on cell line U937. To evaluate the IC50 of the complexes, stock solutions of the 
complexes were prepared dissolving the compounds in DMSO with a concentration of 
10 mg/mL.  U937 cells were cultured in RPMI-1640 medium with a density of 1.5·10
5
 
cell/mL. After 24h cells were transferred into a microtiter plate with 96 plates, treated 
with DMSO 0.1% (v/v) as control and with complex at different times. Cell 
proliferation was measured using Cell-Titer 96
®
 Aqueous One Solution; an hour before 
the end of the treatment 20 µL of MTS solution were added in every plate. MTS 
becomes reduced from tetrazole to formazan. These reductions take place in 
mitochondria only when reductase enzymes are active and therefore conversion is used 
as a measure of viable (living) cells. Formazan is a colored compound with a maximum 
of absorbance at 490 nm. Using a particular spectrofluorimeter (Multiskan Acent, 
Thermo Labsystem, Helsinki, Finland) for microtiter plates it is possible to know the 
number of living cells. Every experiment was repeated three times to build a calibration 
curve. After 5 minutes cells were put in a hemocytometer and counted manually with an 
inverted microscope. 
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4.4.1 Cell growth inhibition of ligands and complexes  
Looking at the biological activity table (Tab. 4.3) of these compounds it is possible to 
do some considerations. 
 
Q IC50(µM) FI IC50(µM) SI IC50(µM) 
QN42M 0.82     
CuQN42M 0.48 CuFIN42M 0.84   
NiQN42M 8.69     
QN41M 2.25 FIN41M >100 SIN41M >100 
CuQN41M 2.25 CuFIN41M 2.62 CuSIN41M >100 
NiQN41M 12.05     
QN41Ph 12.05 FIN41Ph   >100 SIN41Ph  >100 
CuQN41Ph 1.8 CuFIN41Ph 2.94 CuSIN41Ph >100 
QN21Me >100     
CuQN21Me 16.2 CuFIN41E 2.74   
NiQN21Me >100     
QN42H 55     
CuQN42H 4.1     
NiQN42H 42     
 
Table 4.3 – IC50 values on U937 cell inhibition of free and complexed 
thiosemicarbazones 
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4.4.2 Quinolines derivatives 
At first glance, it is apparent that substituents on the thiosemicarbazide nitrogens play 
an important role in the activity of these compounds. IC50 values extend over a range 
between 0.82μM to over 100μM. The best activity (0.82μM) is shown by the derivative 
with two methyls on the terminal nitrogen and it already worsens for the 
monomethylated analogue (2.25μM). The phenyl substituted has an increase in the IC50 
value (12.05μM) but for the free N terminal derivative the IC50 bounces to 55μM. 
Methylation of N2 causes the worst effect and the molecule presents no significant 
activity below the 100μM concentration. 
 
4.4.3 Quinoline metal complexes 
Comparing ligands and their metal complexes it is noteworthy that all copper(II) 
complexes show the best IC50 values, from 0.48 µM for CuQN42M to 16.2 µM for 
CuQN21Me. The free ligand QN21M and its nickel complex NiQN21M have no effect 
for concentrations lower than 100μM.  
Efficacy of the compound is not only a matter of metal but also a matter of substituents, 
as noticed before, methyl substituent on N2 not only reduces the activity of the ligand 
but also that of the complexes in particular that of nickel derivatives (>100 µM) while 
copper complexes is still appreciable (16.2 µM). 
 
4.4.4  Fluoro isatin 
In the case of isatin derivatives we have unfortunately access to less assays but we can 
see that also in this case copper derivatives show a good activity with IC50 values in the 
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range 0.84 - 2.94 μM. These are a little bit lower than the copper quinoline analogues 
but higher than those of nickel. A remarkable case is the thiosemicarbazone with a 
methyl in position 2, which results to be much more active than both copper and nickel 
complexes of the quinoline series. Also this kind of derivatives follows the trend of an 
increase of biological activity passing from a N2 methylated to a N4 monomethylated 
and to N4 dimethylated. Although these difference are not so marked, the N4 
dimethylated presents a noteworthy IC50 of 0.84 µM compared to 2.94 µM of the N2 
methylated and 2.62 µM of the N4 monomethylated. 
 
4.4.5 Sodium isatin-5-sulfonate 
Isatin sulfonate derivatives independently from the nature of the substituents or metal 
complexes do not inhibit cellular proliferation up to concentrations of 100μM. This is 
probably due to the presence of a negative charge of the sulfonate group and supports 
the hypothesis of passive diffusion through the cell membrane.  
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4.5 Topoisomerase IIα inhibition assays 
Inhibition assays were performed using a kit which uses eukaryotic topoisomerase-IIα 
(TopoGen). 14 µL of H2O, 4 µL of buffer solution, 1 µL of supercoiled DNA and 1 µL 
of topoisomerase-IIα are mixed in a microcentrifuge tube (1.7 mL). The drug was added 
as a 2 µL of a stock solution in DMSO and then water was added until a final volume of 
20 µL was reached. The reaction mixture was shaken with care, shortly centrifuged and 
incubated at 37°C for 30’. Subsequently 2 µL of SDS 10%  were added to quench the 
reaction, 2 µL of proteinaseK to digest the remaining proteins. The reaction mixture was 
newly incubated at 37°C for 15’. After this second incubation 2.5 µL of (10X) were 
loaded, the tube shaken and centrifuged. The resultant reaction solutions were loaded 
onto 1% agarose gel and electrophoresed for 5 h at 5 V/cm to separate the possible 
products: supercoiled DNA, linear DNA and relaxed DNA. The gel was incubated with 
a solution of TAE containing ethidium bromide (5 µg/L). For visualization a BioRad 
Fluor-S MultiImager
TM
 was used. 
 
4.5.1 Ligands and metal complexes topoisomerase IIα inhibition  
Concerning topoisomerase IIα activity, we ran an electrophoresis gel (Fig. 4.9) for the 
most active ligand (the dimethylated quinoline thiosemicarbazone, QN42M, and its 
copper and nickel complexes CuQN42M and NiQN42M ), CuQN21M, CuFIN41M and 
CuFIN41Ph . As an overall comment, it is noticeable that copper derivatives are 
effective Topo-IIα inhibitors while the other two seem to have little effect on the 
enzyme.  
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Figure 4.9 – 1. Linear DNA; 2. Plasmidic DNA + Topo-II without 
inhibitors (Topo-II positive); 3. Plasmidic DNA without Topo-II (Topo-
II negative) (supercoiled); 4. DMSO; 5. RPMI 1640 medium; 6. QN42M; 
7. CuQN42M; 8. NiQN42M; 9. CuQN21M; 10. CuFIN41M; 11. 
CuFIN41Ph. The concentration of the thiosemicarbazones used in this 
experiment was 50 µM as required by the assay kit. 
The third position is occupied by plasmidic DNA. In this experiment DMSO and RPMI 
1640 medium were also tested to check if they can interfere with Topoisomerase II. The 
tested compounds are from lane 6 to lane 11. The concentration of thiosemicarbazones 
used in this experiment was 50 µM according to the assay kit requirements. 
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4.5.2 Quinoline  
All the compounds tested show activity against Topo-II isomerase exhibit inhibition of 
Topo-II isomerase. The most active ones are the copper thiosemicarbazones with methyl 
on N4. Ligands alone and nickel complex show inhibition but not at the same level of 
the other two, this can be seen looking at the electrophoresis. In fact in lanes with 
NiQN42M (lane 8) and QN42M (lane 6) we can observe topoisomers due to an 
incomplete inhibition of the enzyme while in the two copper complex lanes the ladder is 
not present. 
 
4.5.3  Isatin 
To study how the difference in steric hindrance on N4 affect the activity we chose two 
copper complexes bearing on the terminal nitrogen a methyl and a phenyl group 
respectively. Despite substantial differences in the functionalization, both complexes 
showed high inhibition of Topo-II isomerase.  
 
4.6 Conclusions  
Several thiosemicarbazones of quinoline and isatin have been prepared and these 
compounds have been used to synthesize copper and nickel derivatives.  
X-ray studies revealed that copper quinoline derivatives tend to be square planar with a 
M:L ratio of 1:1 and nickel complexes octahedral with stoichiometry M:L 1:2.  
Part of these compounds, ligands and complexes, were tested on leukemic cell line 
U937 to study proliferation inhibition. The presence of a charged ligand negatively 
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influences the biological activity: in fact neither ligands alone nor their copper 
complexes resulted to be active. 
As far as the other compounds are concerned, also in this case copper complexes are 
more active than the corresponding ligands and nickel derivatives. 
Substitution of N4 influences the biological activity, in particular among all the 
prepared compounds. Thiosemicarbazones with a dimethylated terminal nitrogen 
showed higher activity. 
Some of these compounds were also tested as topoisomerase-IIα inhibitors. Noteworthy 
is the higher activity of copper complexes and the very low activity of the simple ligand  
allows to exclude the role of thiosemicarbazones as simple chelators. The fact that the 
also the nickel derivative is inactive suggests the need for a redox metal, such as copper, 
to make the inhibitor more effective. 
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4.6  Experimental 
TLC were performed on Silica gel Merck 60 F254 aluminium sheets. Flash 
chromatography was performed on MP Silica 63-200 mesh 60Å (EchoChrom™), 1H 
and NMR spectra were recorded on Bruker 300 Avance and Bruker 400 Avance 
spectrometers, at 300 K. The reported J values are referred to H,H coupling constants. 
Chemical shifts are reported as δ values in ppm using the solvent residual peak as 
internal standard. Elemental analysis were recorded on Flash 1112 Series Analyser (CE 
Instruments). 
 
4.6.1 Syntheses of the quinoline-based ligands 
[QN42M]  
(N4-dimethyl-2-formylquinolinethiosemicarbazone) 
 
 
 
To a stirred solution of 4,4-methyl-3-thiosemicarbazide (271 mg, 2.16 mmol) in 
methanol (60 ml) at r.t. was added formyl quinoline (351 mg, 2.16 mmol) and some 
drop of glacial acetic acid. After 1 h a precipitate appeared, the solution was stirred for 
20 h then the solid was collected by filtration and washed with cold ethanol and dried.  
Yield : 42% 
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1
H NMR (330MHz, DMSO-d6): δH (ppm) 8.67 (1H, m, CH arom.), 8.60 (2H, d, J = 8.7 
Hz, NH2), 8.39 (1H, d, J = 8.7 Hz, CH arom.), 8.02 (2H, m, CH arom.), 7.96 (1H, s, 
CH=N), 7.79 (1H, t, J = 7.5 Hz, CH arom.), 7.64 (1H, t, J = 7.5 Hz, CH arom.), 3.87 
(3H, s, N-CH3) 
 
The X-ray structure was solved from data collected on a Siemens AED diffractometer. 
Cu-K (λ = 1.54178 Å) The structure was solved by direct methods and refined using 
SHELXL97. The drawing was plotted using  ORTEPIII. Crystal data:  C13H14N4S1, 
Mr = 258.34, triclinic, space group P -1,  a=9.3005(6), b=11.3588(7), c=6.3554(3) Å, 
=95.809(5) β=96.883 =106.034(4)°, V=634.25(6)Å3, Z=2, ρcalc=1.353Mgm–3,  
T=298.15 K, F(000)=272, crystal size=0.30x0.30x0.60 mm, index range =  0 < h < 11, -
12 < k < 13, -7 < l < 7, collected reflections =2396, unique reflections=2396, refined 
parameters=219, goodness-of-fit =1.214, final R index=0.0794, wR2=0.2352, electronic 
density residues= 0.50 e –1.24 eÅ–3. 
 
 
 
109 
 
[QN41M] 
(N4-methyl-2-formylquinolinethiosemicarbazone) 
 
 
 
To a stirred solution of 4,3-methyl-3-thiosemicarbazide (234.2 mg, 2.16 mmol) in 
ethanol (60 ml) at 0°C was added formyl quinoline (351 mg, 2.16 mmol) and some drop 
of glacial acetic acid. After 30’ a precipitate appeared, the solution was stirred at r.t. for 
24 h, then the solid was collected by filtration and washed with cold ethanol and dried. 
The compound was crystallized from acetonitrile. 
Yield : 78% 
 
1
H NMR (330MHz, DMSO-d6): δH (ppm) 11.87 (1H, s, C=N-NH), 8.81 (1H, q, J = 4.2 
Hz, S=C-NH), 8.45 (1H, d, J = 8.7 Hz, CH arom.), 8.39 (1H, d, J = 8.7 Hz, CH arom.), 
8.23 (1H, s, CH=N), 8.00 (2H, t, J = 7.5 Hz, CH arom.), 7.78 (1H, t, J = 7.8 Hz, CH 
arom.), 7.62 (1H, t, J = 7.5 Hz, CH arom.), 3.07 (3H, d, J = 4.5 Hz, NH-CH3). 
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The X-ray structure was solved from data collected on a Siemens AED diffractometer. 
Cu-K (λ = 1.54178 Å) The structure was solved by direct methods and refined using 
SHELXL97. The drawing was plotted using  ORTEPIII.  Crystal data:  C12H12N4S1, 
Mr =244.32, orthorhombic, space group P 21 21 21,  a=16.0279(6), b=10.1013(4), 
c=7.5821(3) Å, =90.00 β=90.00 =90.00 °, V=1227.56(8) Å3, Z=4, 
ρcalc=1.322Mgm–3,  T=298.15 K, F(000)=512, crystal size =0.50x0.50x0.70 mm, 
index range =  0 < h < 15, -10 < k < 10, 0 < l < 8, collected reflections =1221, unique 
reflections=1221, refined parameters=154, goodness-of-fit =1.351, final R 
index=0.1353, wR2= 0.2336, electronic density residues= 0.78 e –1.22 eÅ–3. 
 
[QN41E] 
(N4-ethyl-2-formylquinolinethiosemicarbazone) 
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To a stirred solution of 4,3-methyl-3-thiosemicarbazide (234.2 mg, 2.16 mmol) in 
ethanol (60 ml) at 0°C was added formyl quinoline (351 mg, 2.16 mmol) and some drop 
of glacial acetic acid. After 30’ a precipitate appeared, the solution was stirred at r.t. for 
24 h, then the solid was collected by filtration and washed with cold ethanol and dried. 
The compound was crystallized from acetonitrile. 
Yield : 42% 
 
1
H NMR (330MHz, DMSO-d6): δH (ppm) 11.82 (1H, s, C=N-NH), 8.87 (1H, t, J = 5.7 
Hz, S=C-NH), 8.46 (1H, d, J = 8.7 Hz, CH arom.), 8.40 (1H, d, J= 8.7 Hz, CH arom.), 
8.24 (1H, s, CH=N), 8.01 (2H, m, CH arom.), 7.78 (1H, t, J = 7.8 Hz, CH arom.), 7.63 
(1H, t, J = 7.2 Hz, CH arom.), 3.65  (2H, m, NH-CH2CH3), 1.19 (3H, t, J = 7.2 Hz, NH-
CH2CH3). 
 
[QN41Al] 
(N4-allyl-2-formylquinolinethiosemicarbazone) 
 
 
 
To a stirred solution of 4,3-methyl-3-thiosemicarbazide (234.2 mg, 2.16 mmol) in 
ethanol (60 ml) at 0°C was added formyl quinoline (351 mg, 2.16 mmol) and some drop 
of glacial acetic acid. After 30’ a precipitate appeared, the solution was stirred at r.t. for 
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24 h, then the solid was collected by filtration and washed with cold ethanol and dried. 
The compound was crystallized from acetonitrile. 
Yield: 32% 
 
1
H NMR (330MHz, DMSO-d6): δH (ppm) 11.91 ppm (1H, s, C=N-NH), 9.02 ppm (1H, 
t, J = 6 Hz, NH-CH2CH3), 8.48 ppm (1H, d, J = 8.7 Hz, CH arom.), 8.39 ppm (1H, d, J 
= 8.7 Hz, CH arom.), 8.25 ppm (1H, s, CH=N), 8.01 ppm (2H, t, J = 7.5 Hz, CH arom.), 
7.78 ppm (1H, t, J = 7.8 Hz, CH arom.), 7.63 ppm (1H, t, J = 7.5 Hz, CH arom.), 5.95 
ppm (1H, m, NH-CH2CH=CH2), 5.17 ppm (2H, m, NH-CH2CH=CH2), 4.27 ppm (2H, 
t, J = 5.7 Hz, NH-CH2CH=CH2) 
 
[QN21M] 
(N (2)-methyl-2-formylquinolinethiosemicarbazone) 
 
 
 
To a stirred solution of 4,3-methyl-3-thiosemicarbazide (468 mg, 3.5 mmol) in ethanol 
(60 ml) at 0°C was added formyl quinoline (560.6 mg, 3.5 mmol) and some drop of 
glacial acetic acid. After 30’ a precipitate appeared, the solution was stirred at r.t. for 24 
h, then the solid was collected by filtration and washed with cold ethanol and dried. The 
compound was crystallized from acetonitrile. 
113 
 
Yield: 74% 
 
1
H NMR (330MHz, DMSO-d6): δH (ppm) 12.20 ppm (1H, s, C=N-NH), 10.39 (1H, s, 
S=C-NHPhe), 8.62 (1H, d, J = 8.4 Hz, CH arom.Quin), 8.40 (1H, d, J = 8.7 Hz, CH 
arom.Quin), 8.35 (1H, s, CH=N), 8.02 (2H, t, J = 9 Hz, CH arom.Quin), 7.79 (1H, t, J = 
7.5 Hz, CH arom.Quin), 7.64 (1H, t, J = 7.5 Hz, CH arom.Quin), 7.57 (2H, d, J = 8.1 
Hz, CH arom.Phe), 7.41 (2H, t, J = 7.5 Hz, CH arom.Phe), 7.26 (1H, t, J = 7.5 Hz, CH 
arom.Phe) 
 
 
The X-ray structure was solved from data collected on a Siemens AED diffractometer. 
Cu-K (λ = 1.54178 Å) The structure was solved by direct methods and refined using 
SHELXL97. The drawing was plotted using  ORTEPIII.  Crystal data:  C12H12N4S1, 
Mr =244.32, monoclinic, space group P 21/n, a=10.3280(8), b=10.713(2), 
c=11.0160(10) Å, =90.00 β=95.600(7) =90.00 °, V=1213.0(3) Å3, Z=4, ρcalc=1.338 
Mgm–3,  T=298.15 K, F(000)=512, crystal size =0.40x0.40x0.40 mm, index range =  -
12 < h < 12, 0 < k < 13, 0 < l < 13, collected reflections =2410, unique 
reflections=2294, refined parameters=154, goodness-of-fit =1.175, final R 
index=0.1128, wR2= 0.2640, electronic density residues= 0.59 e –1.00 eÅ–3. 
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[QN41Ph]  
(N4-phenyl-2-formylquinolinethiosemicarbazone) 
 
 
 
To a stirred solution of 4,3-methyl-3-thiosemicarbazide (412.5 mg, 3.9 mmol) in 
ethanol (60 ml) at 0°C was added formyl quinoline (616.5 mg, 3.9 mmol) and some 
drop of glacial acetic acid. After 30’ a precipitate appeared, the solution was stirred at 
r.t. for 24 h, then the solid was collected by filtration and washed with cold ethanol and 
dried. The compound was crystallized from acetonitrile. 
Yield: 52% 
 
1
H NMR (330MHz, DMSO-d6): δH (ppm) 8.67 (1H, m, CH arom.), 8.60 (2H, d, J = 8.7 
Hz, NH2), 8.39 (1H, d, J = 8.7 Hz, CH arom.), 8.02 (2H, m, CH arom.), 7.96 (1H, s, 
CH=N), 7.79 (1H, t, J = 7.5 Hz, CH arom.), 7.64 (1H, t, J = 7.5 Hz, CH arom.), 3.87 
(3H, s, N-CH3) 
 
[QN42H] 
(2-formylquinolinethiosemicarbazone) 
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To a stirred solution of 4,3-methyl-3-thiosemicarbazide (337.6 mg, 3.7 mmol) in 
ethanol (60 ml) at 0°C was added formyl quinoline (582.1 mg, 3.7 mmol) and some 
drop of glacial acetic acid. After 30’ a precipitate appeared, the solution was stirred at 
r.t. for 24 h, then the solid was collected by filtration and washed with cold ethanol and 
dried. The compound was crystallized from acetonitrile. 
Yield: 77% 
 
1
H NMR (330MHz, DMSO-d6): δH (ppm) 8.67 (1H, m, CH arom.), 8.60 (2H, d, J = 8.7 
Hz, NH2), 8.39 (1H, d, J = 8.7 Hz, CH arom.), 8.02 (2H, m, CH arom.), 7.96 (1H, s, 
CH=N), 7.79 (1H, t, J = 7.5 Hz, CH arom.), 7.64 (1H, t, J = 7.5 Hz, CH arom.), 3.87 
(3H, s, N-CH3) 
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4.7.2 Syntheses of the quinoline-based complexes 
CuQN42M 
[Cu(QN42M)Cl] 
 
To a stirred solution of QN42M (0.62 mg, 0.23 mmol) in hot ethanol (20mL) was added 
an equimolar quantity of CuCl2·2H2O (0.40 mg, 0.23 mmol). The solution became 
immediately dark and a precipitate appeared. Stirring was continued for 2h under reflux 
then the solution was cooled at r.t and the precipitate collected by filtration and 
crystallized from ethanol 
Yield: 46% 
 
Elem. An. C13H13ClCuN4S, C, 48.78%; H, 3.68%; N, 15.72%; found C, 43.41%; H, 
3.43%; N, 17.35% 
 
 
The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
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plotted using  ORTEPIII.  Crystal data: C13H13Cl1Cu1N4S1, Mr =356.32, monoclinic, 
space group P 21/a,  a=8.443(2), b=19.779(5), c=8.638(2) Å, =90.00 β=101.778(3) 
=90.00 °, V=1412.1(6) Å3, Z=4, ρcalc=1.676 Mgm–3,  T=298.15 K, F(000)=724, 
crystal size =0.30x0.50x0.60 mm, index range = -11 < h < 11, -27 < k < 27, -12 < l < 
12, collected reflections =18792, unique reflections=4055, refined parameters=181, 
goodness-of-fit =0.737, final R index=0.0747, wR2= 0.1651, electronic density 
residues= 0.96 e –0.96 eÅ–3. 
 
NiQN42M 
[Ni(QN42M)2] 
 
To a stirred solution of QN42M (0.44 mg, 0.17 mmol) in hot methanol (35mL) was 
added an equimolar quantity of NiCl2·6H2O (0.41 mg, 0.17 mmol). The solution turn 
immediately to dark orange. Stirring was continued for 5h under reflux then the solution 
was cooled to r.t. After slow solvent evaporation a microcrystalline orange-brown solid 
was obtained which was recrystallized from methanol/ethanol (1:1) 
Yield: 56% 
 
Elem. An. C26H28Cl2 N8NiS2, C, 48.32%; H, 4.38%; N, 17.33%; found C, 16.54%; H, 
4.86%; N, 5.86% 
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The X-ray structure was solved from data collected on a Siemens AED diffractometer. 
Cu-K (λ = 1.54178 Å) The structure was solved by direct methods and refined using 
SHELXL97. The drawing was plotted using  ORTEPIII.      Crystal data:  
C26H28Cl2N8Ni1S2, Mr =646.29, triclinic, space group P -1,  a=9.8780(7), 
b=12.4010(8), c=12.8510(6) Å, =87.750(3) β=76.814(5) =74.760(5)°, 
V=1478.45(16) Å3, Z=2, ρcalc=1.452 Mgm–3,  T=298.15 K, F(000)=668, crystal size 
=0.30x0.40x0.40 mm, index range = 0 < h < 12, -15 < k < 15, 0 < l < 15, collected 
reflections =5591, unique reflections=5591, refined parameters=348, goodness-of-fit 
=1.736, final R index=0.1443, wR2= 0.3670, electronic density residues= 2.23 e –3.60 
eÅ–3. 
 
CuQN41M 
[Cu(QN41M)Cl] 
 
To a stirred solution of QN41M (0.45 mg, 0.19 mmol) in hot acetonitrile (50mL) was 
added an equimolar quantity of CuCl2·2H2O (0.31 mg, 0.19 mmol). The solution 
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became immediately green and a precipitate appeared. Stirring was continued for 2h 
under reflux then the solution was cooled at r.t and the precipitate collected by filtration, 
the filtrate washed with acetonitrile and crystallized from ethanol/acetonitrile (1:2) 
Yield: 39% 
 
Elem. An. C12H11ClCuN4S, C, 37.99%; H, 3.98%; N, 14.77%; found C, 38.21%; H, 
3.84%; N, 14.64% 
 
The X-ray structure was solved from data collected on a Siemens AED diffractometer. 
Cu-K (λ = 1.54178 Å) The structure was solved by direct methods and refined using 
SHELXL97. The drawing was plotted using ORTEPIII. Crystal data:  
C12H11Cl1Cu1N4S1, Mr = 342.30, monoclinic, space group P 21/n,  a=9.7210(5), 
b=10.1550(10), c=13.0880(10) Å, =90.00 β=103.410(7) =90.00 °, V=1256.78(17) 
Å3, Z=4, ρcalc=1.809 Mgm–3,  T=298.15 K, F(000)=692, crystal size=0.40x0.40x0.50 
mm, index range =  0 < h < 11, -11 < k < 11, -15 < l < 15, collected reflections =2460, 
unique reflections=2361, refined parameters=172, goodness-of-fit =1.035, final R 
index=0.0399, wR2=0.1058, electronic density residues= 0.52 e –0.68 eÅ–3. 
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NiQN41M 
[Ni(QN41M)2] 
 
To a stirred solution of QN41M (0.65 mg, 0.26 mmol) in hot ethanol (50mL) was added 
an equimolar quantity of NiCl2·6H2O (0.59 mg, 0.26 mmol). The solution turn 
immediately to dark red. Stirring was continued for 2h under reflux then the solution 
was cooled to r.t. After slow solvent evaporation a microcrystalline orange-brown solid 
was obtained which was recrystallized from methanol/ethanol (1:1). 
Yield: 51% 
 
Elem. An. C26H28Cl2 N8NiS2, C, 52.84%; H, 4.06%; N, 20.54%; found C, 44.64%; H, 
3.84%; N, 16.76% 
 
The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using  ORTEPIII.  Crystal data:  C24H22N8NiS2, Mr=545.33, monoclinic, 
space group P 21/c,  a=16.3250(8), b=9.8130(5), c=16.5410(8) Å, =90.00 
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β=108.4460(10) =90.00 °, V= 2513.7(2) Å3, Z=4, ρcalc=1.441 Mgm–3,  T=298.15 K, 
F(000)=1128, crystal size =0.50x0.60x0.60 mm, index range = -24 < h < 24, -14 < k < 
14, -24 < l < 24, collected reflections =40762, unique reflections=8305, refined 
parameters=316, goodness-of-fit =1.033, final R index=0.0487, wR2= 0.1140, 
electronic density residues= 1.37 e –0.21 eÅ–3. 
 
CuQN41E 
[Cu(QN41E)Cl] 
 
To a stirred solution of QN41E (0.63 mg, 0.25 mmol) in hot methanol (50mL) was 
added an equimolar quantity of CuCl2·2H2O (0.41 mg, 0.25 mmol). The solution 
became immediately dark green and a precipitate appeared. Stirring was continued for 
2h under reflux then the solution was cooled at r.t and the green precipitate collected by 
filtration, washed with methanol 
Yield: 74% 
 
Elem. An. C13H13ClCuN4S, C, 39.80%; H, 4.37%; N, 14.28%; found C, 39.57%; H, 
4.08%; N, 13.69% 
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NiQN41M 
[Ni(QN41M)2] 
 
To a stirred solution of QN41E (0.57 mg, 0.22 mmol) in hot methanol (50mL) was 
added an equimolar quantity of NiCl2·6H2O (0.59 mg, 0.26 mmol). The solution turn 
immediately to dark red. Stirring was continued for 5h under reflux then the solution 
was cooled to r.t. After slow solvent evaporation a microcrystalline orange-brown solid 
was obtained. 
Yield: 41% 
 
Elem. An. C26H28N8NiS2, C, 54.46%; H, 4.57%; N, 19.54%; found C, 35.87%; H, 
4.55%; N, 12.66% 
 
CuQN41Al 
[Cu(QN41Al)Cl] 
 
To a stirred solution of QN41Al (0.76 mg, 0.28 mmol) in hot acetonitrile (30mL) was 
added an equimolar quantity of CuCl2·2H2O (0.48 mg, 0.28 mmol). The solution 
became immediately dark green and a precipitate appeared. Stirring was continued for 
5h under reflux then the solution was cooled at r.t and the dark red precipitate collected 
by filtration, washed with acetonitrile. 
Yield: 42% 
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Elem. An. C14H13ClCuN4S, C, 38.21%; H, 4.81%; N, 12.73%; found C, 37.97%; H, 
3.15%; N, 12.34% 
 
NiQN41Al 
[Ni(QN41Al)2] 
 
To a stirred solution of QN41Al (0.62 mg, 0.23 mmol) in methanol (50mL) was added 
an equimolar quantity of NiCl2·6H2O (0.55 mg, 0.23 mmol). The solution turn 
immediately to dark red. The solution was then refluxed for 5h then cooled to r.t. After 
slow solvent evaporation a microcrystalline orange-brown solid was obtained, which 
was recrystallized from methanol 
Yield: 41% 
 
Elem. An. C26H28N8NiS2, C, 54.46%; H, 4.57%; N, 19.54%; found C, 35.87%; H, 
4.55%; N, 12.66% 
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The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using  ORTEPIII.    Crystal data:  C28H28N8Ni1O1S2, Mr=615.41, triclinic, 
space group P -1,  a=10.3360(13) b=11.9400(14) c=13.3360(16) Å, =105.9110(18) 
β=108.7620(18) =99.6060(19)°, V=1438.7(3) Å3, Z=2, ρcalc=1.421 Mgm–3,  
T=298.15 K, F(000)=640, crystal size =0.30x0.30x0.60 mm, index range = -14 < h < 
14, -16 < k < 16, -18 < l < 18, collected reflections =22296, unique reflections=8333, 
refined parameters=360, goodness-of-fit =0.840, final R index=0.0738, wR2= 0.1498, 
electronic density residues= 0.69 e –0.44 eÅ–3. 
 
CuQN41Ph 
[Cu(QN41Ph)Cl] 
 
To a stirred solution of QN41Ph (0.45 g, 0.15 mmol) in hot methanol (40mL) was 
added an equimolar quantity of CuCl2·2H2O (0.48 g, 0.15 mmol). The solution became 
immediately dark  and a precipitate appeared. Stirring was continued for 4h under reflux 
then the solution was cooled at r.t and the dark red precipitate collected by filtration, 
washed with acetonitrile. 
Yield: 68% 
 
Elem. An. C17H13ClCuN4S, C, 50.49%; H, 3.24%; N, 13.85%; found C, 49.89%; H, 
3.22%; N, 13.67% 
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NiQN41Ph 
[Ni(QN41Ph)2] 
 
To a stirred solution of QN41Ph (0.58 mg, 0.23 mmol) in methanol (80mL) were first 
added some drops of  a solution of NaOH 1N and then an equimolar quantity of 
NiCl2·6H2O (0.45 g, 0.19 mmol). The solution turn immediately to dark red. The 
solution was then refluxed for 5h then cooled to r.t. After slow solvent evaporation a 
microcrystalline orange-brown solid was obtained. 
Yield: 48% 
 
Elem. An. C34H28N8NiS2, C, 61.00%; H, 3.91%; N, 16.74%; found C, 38.60%; H, 
3.13%; N, 10.15% 
 
CuQN21M 
[Cu(QN21M)Cl] 
 
To a stirred solution of QN21M (0.80 g, 0.33 mmol) in hot acetonitrile (70mL) was 
added an equimolar quantity of  CuCl2·2H2O (0.56 g, 0.33 mmol). The solution became 
immediately dark green and a precipitate appeared. Stirring was continued for 6h under 
reflux then the solution was cooled at r.t and the dark red precipitate collected by 
filtration, washed with acetonitrile. 
Yield: 42% 
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Elem. An. C18H16ClCuN4S, C, 38.21%; H, 4.11%; N, 12.25%; found C, 38.21%; H, 
3.78%; N, 12.56% 
 
NiQN21M 
[Ni(QN21M)2] 
 
To a stirred solution of QN41Al (0.88 g, 0.23 mmol) in methanol (50mL) was added an 
equimolar quantity of NiCl2·6H2O (0.55 g, 0.23 mmol). The solution turn immediately 
to dark red. The solution was then refluxed for 20 h then cooled to r.t. After slow 
solvent evaporation a microcrystalline orange-brown solid was obtained, which was 
recrystallized from methanol 
Yield: 41% 
 
Elem. An. C24H23N8NiS2, C, 46.10%; H, 4.99%; N, 17.92%; found C, 28.14%; H, 
4.82%; N, 10.53% 
 
127 
 
 
The X-ray structure was solved from data collected on a Bruker-Siemens SMART AXS 
1000 diffractometer equipped with a CCD detector. Mo-Kα (λ = 0.71069 Å) The 
structure was solved by direct methods and refined using SHELXL97. The drawing was 
plotted using  ORTEPIII. Crystal data:  C24H31Cl2N8Ni1O3.5S2, Mr=625.26, 
monoclino, space group C 2/c,  a=24.5390(13) b=13.9800(8) c=19.4900(11) Å, 
=90.00 β=113.1240(8) =90.00 °, V=6149.0(6)Å3, Z=4, ρcalc=0.675 Mgm–3,  
T=298.15 K, F(000)=1300, crystal size =0.40x0.40x0.40 mm, index range = -30 < h < 
30, -17 < k < 17, -24 < l < 24, collected reflections =36973, unique reflections=6320, 
refined parameters=402, goodness-of-fit =0.986, final R index=0.0681, wR2= 0.1981, 
electronic density residues= 0.54 e –1.36 eÅ–3. 
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CuQN42H 
[Cu(QN42H)Cl] 
 
To a stirred solution of QN41Ph (0.104 g, 0.45 mmol) in hot acetonitrile (30mL) was 
added an equimolar quantity of CuCl2·2H2O (0.77 g, 0.45 mmol). The solution became 
immediately dark green and a precipitate appeared. Stirring was continued for 5h under 
reflux then the solution was cooled at r.t and the dark red precipitate collected by 
filtration, washed with acetonitrile. 
Yield: 58% 
 
Elem. An. C14H13ClCuN4S·4H2O, C, 38.21%; H, 4.81%; N, 12.73%; found C, 37.97%; 
H, 3.15%; N, 12.34% 
 
NiQN42H 
[Ni(QN42H)2] 
 
To a stirred solution of QN41Al (0.88 g, 0.38 mmol) in methanol (50mL) was added an 
equimolar quantity of NiCl2·6H2O (0.91 g, 0.38 mmol). The solution turn immediately 
to dark red. The solution was then refluxed for 5h then cooled to r.t. After slow solvent 
evaporation a microcrystalline orange-brown solid was obtained, which was 
recrystallized from methanol 
Yield: 44% 
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Elem. An. C26H28N8NiS2, C, 54.46%; H, 4.57%; N, 19.54%; found C, 35.87%; H, 
4.55%; N, 12.66% 
 
4.7.3 Syntheses of the isatin-based ligands 
[ISN42M] 
(1-(isatin 5′- sulfonic acid sodium salt)-4-(4′-dimethyl)-3-thiosemicarbazone) 
 
 
 
A stirred solution of 4,4 dimethyl-thiosemicarbazide (97.8 g, 0.8 mmol) and isatin-5-
sulfonic acid sodium salt dehydrate (229.7 g, 0.8 mmol) in MeOH (100 mL) was 
refluxed for 24h. Solution was cooled to r.t. and poured into a crystallizer and the 
solvent was let slowly evaporate. 
 
1
H NMR (300MHz, DMSO-d6): δH (ppm) 13.32 (s, 1H, NHN), 11.35 (s, 1H, NH), 7.75 
(d, J = 1.78 Hz, 1H, CHar), 7.60 (dd, J = 8.07, 1.78 Hz, 1H, CHar), 6.90 (d, J = 8.07 
Hz, 1H, CHar), 3.39 (s, 6H, CH3). 
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[ISN41M] 
(1-(isatin 5′- sulfonic acid sodium salt)-4-(4′-methyl)-3-thiosemicarbazone) 
 
 
 
A stirred solution of 4-Methyl-thiosemicarbazide (130.4 g, 1.25mmol) and isatin-5-
sulfonic acid sodium salt dihydrate (350g, 1.22mmol) in EtOH (50 mL) was refluxed 
for 16 h, during this time a precipitate appeared. After this time the solution was cooled 
at r.t. and filtered, the orange solid washed with EtOH several times and dried. 
Yield: 80% 
 
1
H NMR (300MHz, DMSO-d6): δH (ppm) 12.55 (s, 1H), 9.43 (s, 1H), 8.01 (d, J = 1.38 
Hz, 1H), 7.59 (s, 1H), 6.86 (d, J = 7.87 Hz, 1H), 3.07 (d, J = 4.55 Hz, 3H) 
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[ISN41E] 
(1-(isatin 5′- sulfonic acid sodium salt)-4-(4′-ethyl)-3-thiosemicarbazone) 
 
 
 
A solution of 4-ethyl thiosemicarbazide (258.4 g, 0.87 mmol) and isatin-5-sulfonic acid 
sodium salt dihydrate (250g, 0.87 mmol) in MeOH (150 mL) was cooled to 0°C and 
stirred for overnight. After that the solution was cooled at r.t., poured into a crystallizer 
and the solvent slowly evaporated to obtain yellow crystals which were harvested and 
recrystallized from EtOH/MeOH (3:1). 
Yeld: 76.4% 
 
1
H NMR (300MHz, DMSO-d6): δH (ppm) 12.53 (s, 1H, NH), 11.29 (s, 1H NH), 9.50 (m, 
1H, NH), 8.02 (m, 1H, CHar), 7.57 (m,1H, CHar), 6.87 (d, 1H, CHar), 3.67 (d, J = 7.28 
Hz, 2H, CH2CH3), 1.18 (m, 3H, CH3). 
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[ISN41Ph] 
(1-(isatin 5′- sulfonic acid sodium salt)-4-(4′-phenyl)-3-thiosemicarbazone) 
 
 
 
A solution of 4-phenyl thiosemicarbazide (118.6 g, 0.87 mmol) and isatin-5-sulfonic 
acid sodium salt dihydrate (250g, 0.87 mmol) in MeOH (150 mL) was cooled to 0°C 
and stirred for overnight. After that the solution was cooled at r.t., poured into a 
crystallizer and the solvent slowly evaporated to obtain yellow crystals which were 
harvested and recrystallized from EtOH/MeOH (3:1). 
Yeld: 76.4% 
 
1
H NMR (300MHz, DMSO-d6): δH (ppm) 12.79 (s, 1H, NH), 11.39 (d, 1H NH), 11.02 
(m, 1H, NH), 8.23 (d, Arom), 7.72-7.63 (m, Arom), 7.54-7.47 (dd, Arom), 7.42-7.33 (m, 
Arom), 7.29-7.24 (m, Arom), 6.89-6.87 (m, Arom). 
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[IFN41E]  
(1-(5′-fluoro isatin)-4-(4′-ethyl)-3-thiosemicarbazone) 
 
 
 
A stirred solution of 4-ethyl thiosemicarbazide (258.4 g, 2.16 mmol) and 5-fluoro isatin 
(254g, 2.16 mmol) in MeOH (150 mL) was refluxed for 6h. After that the solution was 
cooled at r.t., poured into a crystallizer and the solvent slowly evaporated to obtain 
yellow crystals which were harvested and recrystallized from EtOH/MeOH (3:1). 
Yeld: 76.4% 
 
1
H NMR (300MHz, DMSO-d6): δH (ppm) 12.46 (s, 1H, NH), 11.22 (s, 1H NH), 9.37 (m, 
1H, NH), 7.50 (m, 1H, CHar), 7.25 (m,1H, CHar), 6.95 (d, J = 4.16 Hz, 1H, CHar), 
3.92 (d, J = 7.28 Hz, 2H, CH2CH3), 1.18 (m, 3H, CH3). 
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[IFN42M] 
(1-(5′-fluoro isatin)-4-(4′-dimethyl)-3-thiosemicarbazone) 
 
 
 
A stirred solution of 4,4-methyl thiosemicarbazide (181 g, 1.51 mmol) and 5-fluoro 
isatin (250.4g, 1.51 mmol) in MeOH (125 mL) was refluxed for 24h cooled at r.t., 
poured into a crystallizer and the solvent slowly evaporated to obtain orange crystals 
which were harvested and recrystallized from EtOH/MeOH (3:1). 
Yield: 87.2% 
 
1
H NMR (300MHz, DMSO-d6): δH (ppm) 13.41 (s, 1H, NH), 11.33 (s, 1H NH), 7.36 
(dd, J = 8.16, 2.58 Hz, 1H, CHar), 7.21 (m, 1H, CHar), 6.96 (dd, J = 8.7, 4.19 Hz, 1H, 
CHar), 3.39 (s, 6H, 2CH3) 
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[IFN41M]  
(1-(5′-fluoro isatin)-4-(4′-methyl)-3-thiosemicarbazone) 
 
 
 
A solution of 4-methy-thiosemicarbazide (350 g, 3.22 mmol) and 5-fluoro isatin (391.9 
g, 3.22 mmol) in EtOH (70 mL) was cooled to 0°C and stirred 24 h 
Yield:  
1
H NMR (300MHz, DMSO-d6): δH (ppm) 12.50 (s, 1H, NH), 9.33 (bm, 1H, NHCH3), 
7.45 (dd, J = 8.25, 2.74 Hz, 1H, CHar), 7.20 (m, 1H, CHar), 6.93 (dd, J = 8.25, 4.30 Hz, 
1H, CHar), 3.09 (d, J = 4.05 Hz, 3H, CH3) 
 
[IFN42Ph]  
(1-(5′-fluoro isatin)-4-(4′-phenyl)-3-thiosemicarbazone) 
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A solution of 4-methy-thiosemicarbazide (206.7 g, 1.22 mmol) and 5-fluoro isatin 
(201.6 g, 1.22 mmol) in EtOH (75 mL) was cooled to 0°C and stirred 24 h, during that 
time a yellow precipitate appeared. After 24 h the precipitate was collected by filtration 
and washed with MeOH. 
Yield: 51% 
 
1
H NMR (300MHz, DMSO-d6): δH (ppm) 12.77 (s, 1H, NH), 11.31 (s, 1H, NH), 11.05 
(s, 1H, NH), 8.14 (d, J = 1.44 Hz, 1H), 7.63 (dd, J = 8.10, 1.73 Hz, 1H), 7.58 (dd, J = 
8.43, 1.03 Hz, 2H), 7.42 (m, 2H), 7.27 (m, 1H) 
 
4.7.4  Syntheses of the isatin-based complexes 
CuIFN41M 
[Cu(IFN41M)Cl] 
 
A solution of IFN41M (0.09 g, 0.35 mmol) and CuCl2·2H2O (61.02 g, 0.35 mmol) in 
MeOH (55 mL) was refluxed for 2 h. During the reaction time a dark green solid 
appeared. The precipitate was collected by filtration.  
Yield: 74% 
 
Elemental analysis : calcd. for C10H8ClCuFN4OS C, 34.29%; H, 2.30%; N, 16.10%, 
found C, 35.11%; H, 2.33%; N, 16.06%, 
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CuISN41M 
[Cu(ISN41M)Cl] 
 
A solution of ISN41M (0.10 g, 0.32 mmol) and CuCl2·2H2O (0.05 g, 0.32 mmol) in 
MeOH (50 mL) was refluxed for 8 h. During that time a solid appeared. After that time 
the precipitate was collected by filtration, washed with methanol and dried. 
Yield: 42%  
Elemental analysis : calcd. for C10H8ClCuN4NaO4S2, C, 27.57; H, 1.85; N, 12.87; found 
C, 27.85%; H, 2.11%; N, 12.50% 
 
CuIFN41E 
[Cu(IFN41E)Cl] 
 
A stirred solution of IFN41E (0.074 g, 0.28 mmol) and CuCl2·2H2O (0.048 g, 0.28 
mmol) in MeOH (50 mL) was refluxed for 8h, during which time a green solid 
precipitate appeared. After 8 h the solution was cooled to r.t. and the precipitate 
collected by filtration. 
Yield: 59% 
 
Elemental analysis : calcd. for C11H10ClCuFN4OS2, C, 36.27%; H, 2.77%; N, 15.38%; 
found C, 35.89%; H, 3.42%; N, 14.01%  
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Cu(ISN41E) 
[Cu(ISN41E)Cl] 
 
To a stirred solution of IFN41E (0.080 g, 0.22 mmol) in MeOH (50 mL) was added 
CuCl2·2H2O (0.038 g, 0.22 mmol).  Then the solution was refluxed, during which time a 
green solid precipitate appeared. After 8 h the solution was cooled to r.t. and the 
precipitate collected by filtration. 
Yield: 97% 
 
Elemental analysis : calcd. for C11H10ClCuN4NaO4S2, C, 29.47%; H, 2.25%; N, 12.50%; 
found C, 28.34%; H, 2.47%; N, 11.49% 
 
CuIFN41Ph 
[Cu(IFN4Ph)Cl] 
 
A stirred solution of IFN4Ar (0.052 g, 0.16 mmol) and CuCl2·2H2O (0.028 g, 0.16 
mmol) in MeOH (50 mL) was refluxed for 8 h, during this period of time a brown/green 
precipitate appeared. After 8 h the precipitate was collected by filtration. 
Yield: 39% 
Elemental analysis : calcd. for C15H10ClCuFN4OS, C, 43.69%; H, 2.44%; N, 13.59%; 
found C, 43.67%; H, 2.34%; N, 13.26% 
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CuISN41Ph) 
[Cu(ISN41Ph)Cl] 
 
To a stirred solution of ISN4Ar (0.1 g, 0.56 mmol) in MeOH (50 mL) were addede 
some drops of NaOH 5M monitoring the pH (8-9) after that was added CuCl2·2H2O 
(0.42 g, 0.56 mmol) and the colour turned dark. Then the solution was refluxed for 8 h, 
cooled to r.t. and poured into a crystallizer and the solvent slowly evaporate to obtain a 
red crystals.  
Yield: 78.2 
 
Elemental analysis : calcd. for C15H10ClCuN4NaO4S2, C, 33.84%; H, 2.65%; N, 10.52%; 
found C, 30.58%; H, 2.67%; N,8.74 %  
 
CuIFN42M 
[Cu(IFN42M)Cl] 
 
To a stirred solution of IFN42M (0.071 g, 0.26 mmol) in MeOH (50 mL) were addede 
some drops of NaOH 5M monitoring the pH (8-9) after that was added CuCl2·2H2O 
(0.044 g, 0.26 mmol) and the colour turned dark. Then the solution was refluxed for 8 h, 
cooled to r.t. and the precipitate collected by filtration. 
Yield: 18.3% 
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Elemental analysis : calcd. for C11H10ClCuFN4OS, C, 36.27%; H, 2.77%; N, 15.38%; 
found C, 36.17%; H, 2.68%; N, 14.93% 
 
CuISN42M 
[Cu(ISN42M)Cl] 
 
To a stirred solution of ISN42M (0.058 g, 0.15 mmol) in MeOH (50 mL) were addede 
some drops of NaOH 5M monitoring the pH (8-9) after that was added CuCl2·2H2O 
(0.026 g, 0.15 mmol) and the colour turned  red-orange. Then the solution was refluxed 
for 8 h, cooled to r.t., poured into a crystallizer and the solvent slowly evaporated. 
Yield: 53% 
 
Elemental analysis : calcd. for C11H10ClCuNaN4O4S2, C, 36.27%; H, 2.77%; N, 15.38%; 
found C, 36.17%; H, 2.68%; N, 14.93% 
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